[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHk10KXvYwF76NPOmyahu_cEc0SBO69S4atLrgHSFg6Q":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"Abramson Cancer Center at Penn Medicine",[4],446,false,133,1,482042,56,263,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Breast Cancer",49,{"name":18,"count":19},"Cancer",22,{"name":21,"count":22},"Lung Cancer",18,{"name":24,"count":25},"Prostate Cancer",16,{"name":27,"count":28},"Ovarian Cancer",13,{"name":30,"count":31},"Head and Neck Cancer",11,{"name":33,"count":31},"Colorectal Cancer",{"name":35,"count":36},"Smoking",10,[38,43,48,53,58,63,68,73,77,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03032406","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","2022-05-17","Hydroxychloroquine",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03757689","Neoadjuvant PD-1 Blockade in Patients with Stage IIB\u002FC Melanoma","2024-12-01","Pembrolizumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04221503","Niraparib\u002FTTFields in GBM","2026-01","Niraparib",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03083288","Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET\u002FCT) in Breast Cancer","2026-02-22","[18F]FluorThanatrace",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT04499534","BRCA1\u002F2 Flu Vaccine","2026-03","Seasonal influenza vaccine",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04332367","Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance","2026-04","Carboplatin",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04339036","CapTemY90 for Grade 2\u002F3 NET Liver Metastases","2026-05-01","Capecitabine Oral Product",{"nctId":74,"briefTitle":75,"date":76,"intervention":47},"NCT05733715","Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma","2026-06",{"nctId":78,"briefTitle":79,"date":80,"intervention":47},"NCT04827862","RADVAX™ for Relapsed\u002FRefractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy","2026-06-01",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT03646617","Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma","2026-06-30","Nivolumab",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,269,343,507,567,624,650,676,745,782,804,826,852,881,907,941,963,994,1012,1030,1059,1083,1108,1132,1150,1168,1193,1218,1236,1254,1282,1300,1318,1336,1354,1409,1478,1500,1525,1543,1573,1591,1609,1632,1658,1680,1705,1799,1821,1839,1863,1886,1913,1940,1958,1976,1995,2019,2071,2130,2156,2189,2219,2254,2296,2332,2354,2388,2423,2460,2493,2530,2559,2581,2599,2623,2641,2659,2682,2710,2728,2752,2770,2788,2811,2873,2898,2916,2939,2964,2989,3013,3031,3049,3067,3088,3106,3130,3155,3173,3198,3216,3244,3262,3280,3298,3341,3359,3384,3402,3420,3438,3463,3481,3504,3529,3547,3571,3589,3614,3643,3661,3679,3701,3719,3737,3755,3773,3791,3813,3838,3869,3907,3944,3968,4002,4024,4052,4082,4105,4129,4158,4176,4200,4223,4241,4266,4284,4302,4328,4346,4364,4386,4404,4430,4448,4466,4489,4507,4525,4543,4561,4583,4601,4619,4637,4655,4673,4691,4709,4727,4745,4763,4786,4804,4822,4845,4863,4881,4905,4923,4941,4959,4983,5006,5030,5048,5066,5084,5106,5128,5150,5173,5196,5220,5244,5267,5291,5318,5340,5367,5392,5415],{"intervention":47,"totalTrials":95,"cells":96},15,{"EARLY_PHASE1":97,"PHASE1":109,"PHASE2":159,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":98,"activeCount":9,"soonestReadout":76},[99],{"nctId":74,"briefTitle":75,"status":100,"phases":101,"primaryCompletion":76,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":107},"RECRUITING",[87],"2028-01","2023-05-03",30,[106],"Renal Cell Carcinoma",[47,108],"Lenvatinib",{"trials":110,"activeCount":9,"soonestReadout":127},[111,123,135,147],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT02303990","RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers","COMPLETED",[88],"2018-12","2019-12-31","2015-01-08",59,[121],"Metastatic Cancers",[47],{"nctId":124,"briefTitle":125,"status":100,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT03760575","Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)",[88],"2027-02-01","2023-01-10",20,[131],"Mesotheliomas Pleural",[47,133,134],"Cisplatin","Pemetrexed",{"nctId":136,"briefTitle":137,"status":138,"phases":139,"primaryCompletion":140,"completion":116,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT02880345","RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1\u002FPD-L1 Monotherapy","WITHDRAWN",[88],"2017-08","2016-08",0,[144],"Urothelial Cancer",[146],"PEMBROLIZUMAB",{"nctId":148,"briefTitle":149,"status":114,"phases":150,"primaryCompletion":151,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT02434354","A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma",[88],"2019-07","2021-09-29","2015-04",33,[156],"Malignant Melanoma",[158],"pembrolizumab",{"trials":160,"activeCount":252,"soonestReadout":46},[161,173,184,193,202,215,225,233,243],{"nctId":162,"briefTitle":163,"status":100,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"NCT07082439","Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma",[89],"2027-09","2029-09","2025-09-10",27,[170],"Colorectal Adenocarcinoma Metastatic in the Liver",[47,172],"Odetiglucan",{"nctId":174,"briefTitle":175,"status":114,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT02316002","Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer",[89],"2018-09-30","2022-12","2015-01-21",51,[182],"Oligometastatic Non-small Cell Lung Cancer (NSCLC)",[47],{"nctId":185,"briefTitle":186,"status":138,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":142,"conditions":190,"interventions":192},"NCT03586024","Pembrolizumab in Relapsed or Refractory Extranodal NK\u002FT- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas",[88,89],"2020-08-19","2019-03-12",[191],"Lymphoma",[47],{"nctId":78,"briefTitle":79,"status":194,"phases":195,"primaryCompletion":80,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"ACTIVE_NOT_RECRUITING",[89],"2026-11","2022-07-01",6,[200],"Non Hodgkin Lymphoma",[47],{"nctId":203,"briefTitle":204,"status":114,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":214},"NCT02650999","Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas",[88,89],"2019-02-25","2020-06-12","2016-01",12,[211,212,213],"CD19+ Diffuse Large B-cell Lymphomas","Follicular Lymphomas","Mantle Cell Lymphomas",[47],{"nctId":216,"briefTitle":217,"status":114,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":224},"NCT03087760","Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer",[89],"2023-09-12","2017-11-29",32,[223],"Non-small Cell Lung Cancer",[47],{"nctId":44,"briefTitle":45,"status":194,"phases":226,"primaryCompletion":46,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},[89],"2027-02","2019-05-06",63,[231],"Melanoma",[47],{"nctId":234,"briefTitle":235,"status":100,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":95,"conditions":240,"interventions":242},"NCT05496036","Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma",[89],"2026-12-31","2027-09-30","2023-02-13",[241],"Merkel Cell Carcinoma",[47],{"nctId":244,"briefTitle":245,"status":194,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":168,"conditions":250,"interventions":251},"NCT04454528","BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy",[88,89],"2026-08","2027-08","2020-12-07",[15],[47],5,{"trials":254,"activeCount":142},[],{"trials":256,"activeCount":142},[],{"trials":258,"activeCount":142},[259],{"nctId":260,"briefTitle":261,"status":114,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT02791594","Imaging FDG Flare in Melanoma",[],"2020-07-01","2016-06",21,[267],"Metastatic Melanoma",[47],{"intervention":270,"totalTrials":198,"cells":271},"Ipilimumab",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":286,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":273,"activeCount":142},[],{"trials":275,"activeCount":142},[276],{"nctId":277,"briefTitle":278,"status":279,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":9,"conditions":283,"interventions":285},"NCT04429321","Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary","TERMINATED",[88],"2024-01-31","2020-08-26",[106,284],"Renal Cell Carcinoma Stage IV",[85,270],{"trials":287,"activeCount":336,"soonestReadout":84},[288,298,308,315,324],{"nctId":289,"briefTitle":290,"status":279,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":31,"conditions":294,"interventions":297},"NCT03693846","Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors",[89],"2021-03-06","2019-02-15",[295,296],"Mucinous Adenocarcinoma of the Colon","Mucinous Adenocarcinoma of the Rectum",[85,270],{"nctId":299,"briefTitle":300,"status":194,"phases":301,"primaryCompletion":247,"completion":247,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT04013854","Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab",[89],"2020-01-01",67,[305,231],"Melanoma Stage III",[307,270],"nivolumab",{"nctId":82,"briefTitle":83,"status":100,"phases":309,"primaryCompletion":84,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":314},[89],"2027-12-31","2018-11-27",54,[267],[85,270],{"nctId":316,"briefTitle":317,"status":114,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":19,"conditions":322,"interventions":323},"NCT01497808","RADVAX™: A STRATIFIED PHASE I\u002FII DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA",[88,89],"2013-12-29","2015-10-12","2011-11-29",[267],[270],{"nctId":325,"briefTitle":326,"status":100,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":334},"NCT06747845","Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy",[89],"2028-06","2029-01-30","2025-05-07",68,[333],"Pancreatic Adenocarcinoma Metastatic",[52,335,270],"FOLFIRI",3,{"trials":338,"activeCount":142},[],{"trials":340,"activeCount":142},[],{"trials":342,"activeCount":142},[],{"intervention":42,"totalTrials":28,"cells":344},{"EARLY_PHASE1":345,"PHASE1":357,"PHASE2":416,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":346,"activeCount":142},[347],{"nctId":348,"briefTitle":349,"status":114,"phases":350,"primaryCompletion":351,"completion":351,"start":352,"enrollment":198,"conditions":353,"interventions":355},"NCT01396200","Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine",[87],"2012-10","2011-06",[354],"Myeloma",[42,356],"Rapamycin",{"trials":358,"activeCount":142},[359,372,383,393,406],{"nctId":360,"briefTitle":361,"status":114,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT00909831","Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment",[88],"2012-05","2013-11","2008-10",40,[368],"Unspecified Adult Solid Tumor, Protocol Specific",[370,371],"hydroxychloroquine","temsirolimus",{"nctId":373,"briefTitle":374,"status":114,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT00568880","Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma",[88],"2011-06-22","2010-09-08",25,[380],"Multiple Myeloma and Plasma Cell Neoplasm",[382,370],"bortezomib",{"nctId":384,"briefTitle":385,"status":114,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":129,"conditions":389,"interventions":390},"NCT03215264","To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer",[88],"2020-06-01","2017-10-02",[33],[370,391,392],"entinostat","regorafenib",{"nctId":394,"briefTitle":395,"status":114,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":402},"NCT00714181","Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors",[88],"2011-07","2013-06","2008-06",38,[368],[370,403,404,405],"temozolomide","TdT-mediated dUTP nick end labeling assay","western blotting",{"nctId":407,"briefTitle":408,"status":114,"phases":409,"primaryCompletion":410,"completion":411,"start":398,"enrollment":412,"conditions":413,"interventions":414},"NCT01897116","A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",[88],"2016-07-12","2016-10-05",8,[231],[42,415],"Vemurafenib",{"trials":417,"activeCount":500,"soonestReadout":41},[418,435,444,454,465,476,487],{"nctId":419,"briefTitle":420,"status":114,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":430},"NCT01206530","FOLFOX\u002FBevacizumab\u002FHydroxychloroquine (HCQ) in Colorectal Cancer",[88,89],"2017-09","2010-09",50,[426,427,428,429],"Rectal Cancer","Colon Cancer","Metastasis","Adenocarcinoma",[42,431,432,433,433,434],"Oxaliplatin","Leucovorin","5-fluorouracil","Bevacizumab",{"nctId":39,"briefTitle":40,"status":194,"phases":436,"primaryCompletion":41,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},[89],"2026-01-01","2017-01-23",53,[441],"Breast Cancer Stage IIB",[42,443],"Everolimus",{"nctId":445,"briefTitle":446,"status":138,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":142,"conditions":451,"interventions":452},"NCT03400254","Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")",[88,89],"2019-08-30","2019-11-12","2019-02-26",[15],[42,453],"Gedatolisib",{"nctId":455,"briefTitle":456,"status":114,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":424,"conditions":460,"interventions":462},"NCT02257424","Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",[88,89],"2021-10","2014-10",[461],"Advanced BRAF Mutant Melanoma",[463,370,464],"Trametinib 2 mg daily","dabrafenib 150 mg orally twice a day",{"nctId":466,"briefTitle":467,"status":100,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT04523857","ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer",[89],"2027-12","2028-12","2021-11-01",44,[15],[475,42],"Abemaciclib",{"nctId":477,"briefTitle":478,"status":114,"phases":479,"primaryCompletion":480,"completion":481,"start":482,"enrollment":366,"conditions":483,"interventions":485},"NCT01510119","Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I\u002FII Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma",[88,89],"2016-04-04","2017-01-05","2011-09",[484],"Metastatic Clear Cell Renal Cell Carcinoma",[42,486],"RAD001",{"nctId":488,"briefTitle":489,"status":114,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":497},"NCT01506973","A Study of Hydroxychloroquine in Combination With Gemcitabine\u002FAbraxane in Pancreatic Cancer",[88,89],"2022-03","2011-12",119,[495,496],"Advanced Adenocarcinoma","Metastatic Adenocarcinoma",[42,498,499],"Gemcitabine","Abraxane",2,{"trials":502,"activeCount":142},[],{"trials":504,"activeCount":142},[],{"trials":506,"activeCount":142},[],{"intervention":85,"totalTrials":508,"cells":509},7,{"EARLY_PHASE1":510,"PHASE1":523,"PHASE2":529,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":511,"activeCount":142},[512],{"nctId":513,"briefTitle":514,"status":279,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":336,"conditions":518,"interventions":520},"NCT03519308","A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer",[87],"2022-04-18","2020-07-29",[519],"Pancreatic Cancer",[85,521,498,522],"Nab-Paclitaxel","Paricalcitol",{"trials":524,"activeCount":142},[525],{"nctId":277,"briefTitle":278,"status":279,"phases":526,"primaryCompletion":281,"completion":281,"start":282,"enrollment":9,"conditions":527,"interventions":528},[88],[106,284],[85,270],{"trials":530,"activeCount":500,"soonestReadout":84},[531,535,539,543,552],{"nctId":289,"briefTitle":290,"status":279,"phases":532,"primaryCompletion":292,"completion":292,"start":293,"enrollment":31,"conditions":533,"interventions":534},[89],[295,296],[85,270],{"nctId":299,"briefTitle":300,"status":194,"phases":536,"primaryCompletion":247,"completion":247,"start":302,"enrollment":303,"conditions":537,"interventions":538},[89],[305,231],[307,270],{"nctId":82,"briefTitle":83,"status":100,"phases":540,"primaryCompletion":84,"completion":310,"start":311,"enrollment":312,"conditions":541,"interventions":542},[89],[267],[85,270],{"nctId":544,"briefTitle":545,"status":279,"phases":546,"primaryCompletion":547,"completion":547,"start":548,"enrollment":508,"conditions":549,"interventions":551},"NCT03781960","Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma",[89],"2022-04-29","2019-07-31",[550],"Hepatocellular Carcinoma",[475,85],{"nctId":553,"briefTitle":554,"status":279,"phases":555,"primaryCompletion":556,"completion":556,"start":557,"enrollment":508,"conditions":558,"interventions":560},"NCT03495713","Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS",[89],"2022-04-20","2018-11-02",[559],"Hodgkin Lymphoma",[85],{"trials":562,"activeCount":142},[],{"trials":564,"activeCount":142},[],{"trials":566,"activeCount":142},[],{"intervention":568,"totalTrials":252,"cells":569},"Paclitaxel",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":610,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":571,"activeCount":142},[],{"trials":573,"activeCount":9,"soonestReadout":237},[574,584,594,602],{"nctId":575,"briefTitle":576,"status":114,"phases":577,"primaryCompletion":578,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":582},"NCT01320592","PD0332991\u002FPaclitaxel in Advanced Breast Cancer",[88],"2019-05","2011-03",28,[15],[583,568],"PD0332991",{"nctId":585,"briefTitle":586,"status":114,"phases":587,"start":588,"enrollment":209,"conditions":589,"interventions":590},"NCT00025480","Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",[88],"2001-08",[21],[591,592,593],"carboplatin","paclitaxel","tipifarnib",{"nctId":595,"briefTitle":596,"status":194,"phases":597,"primaryCompletion":237,"completion":237,"start":598,"enrollment":104,"conditions":599,"interventions":601},"NCT02213497","Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer",[88],"2014-04",[600],"Esophageal Cancer",[67,568],{"nctId":603,"briefTitle":604,"status":114,"phases":605,"primaryCompletion":189,"completion":189,"start":208,"enrollment":22,"conditions":606,"interventions":608},"NCT02599363","A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer",[88],[607],"Advanced Breast Cancer",[609,568],"Ribociclib",{"trials":611,"activeCount":9,"soonestReadout":66},[612],{"nctId":64,"briefTitle":65,"status":100,"phases":613,"primaryCompletion":66,"completion":66,"start":614,"enrollment":119,"conditions":615,"interventions":616},[89],"2020-08-01",[223],[67,568,617],"Ramucirumab",{"trials":619,"activeCount":142},[],{"trials":621,"activeCount":142},[],{"trials":623,"activeCount":142},[],{"intervention":67,"totalTrials":336,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":638,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":627,"activeCount":142},[],{"trials":629,"activeCount":9,"soonestReadout":237},[630,634],{"nctId":585,"briefTitle":586,"status":114,"phases":631,"start":588,"enrollment":209,"conditions":632,"interventions":633},[88],[21],[591,592,593],{"nctId":595,"briefTitle":596,"status":194,"phases":635,"primaryCompletion":237,"completion":237,"start":598,"enrollment":104,"conditions":636,"interventions":637},[88],[600],[67,568],{"trials":639,"activeCount":9,"soonestReadout":66},[640],{"nctId":64,"briefTitle":65,"status":100,"phases":641,"primaryCompletion":66,"completion":66,"start":614,"enrollment":119,"conditions":642,"interventions":643},[89],[223],[67,568,617],{"trials":645,"activeCount":142},[],{"trials":647,"activeCount":142},[],{"trials":649,"activeCount":142},[],{"intervention":52,"totalTrials":500,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":653,"activeCount":142},[],{"trials":655,"activeCount":142},[],{"trials":657,"activeCount":500,"soonestReadout":51},[658,666],{"nctId":49,"briefTitle":50,"status":194,"phases":659,"primaryCompletion":51,"completion":51,"start":660,"enrollment":104,"conditions":661,"interventions":665},[89],"2019-12-30",[662,663,664],"Glioblastoma","Recurrent Glioblastoma","GBM",[52],{"nctId":325,"briefTitle":326,"status":100,"phases":667,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":668,"interventions":669},[89],[333],[52,335,270],{"trials":671,"activeCount":142},[],{"trials":673,"activeCount":142},[],{"trials":675,"activeCount":142},[],{"intervention":431,"totalTrials":252,"cells":677},{"EARLY_PHASE1":678,"PHASE1":690,"PHASE2":692,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":679,"activeCount":142},[680],{"nctId":681,"briefTitle":682,"status":279,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT03427021","A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity",[87],"2018-10-23","2017-02-01",65,[688],"GI Patients on Oxaliplatin Containing Regimen",[431],{"trials":691,"activeCount":142},[],{"trials":693,"activeCount":9,"soonestReadout":725},[694,707,711,720],{"nctId":695,"briefTitle":696,"status":279,"phases":697,"primaryCompletion":698,"completion":699,"start":700,"enrollment":252,"conditions":701,"interventions":702},"NCT00602329","MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer",[89],"2009-07","2009-10","2006-02",[33],[703,704,705,706],"bevacizumab","fluorouracil","leucovorin calcium","oxaliplatin",{"nctId":419,"briefTitle":420,"status":114,"phases":708,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":709,"interventions":710},[88,89],[426,427,428,429],[42,431,432,433,433,434],{"nctId":712,"briefTitle":713,"status":114,"phases":714,"primaryCompletion":482,"completion":482,"start":715,"enrollment":716,"conditions":717,"interventions":718},"NCT00602602","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",[89],"2007-03",19,[519],[703,704,719,706],"gemcitabine hydrochloride",{"nctId":721,"briefTitle":722,"status":723,"phases":724,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":733},"NCT07059611","Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","NOT_YET_RECRUITING",[89],"2027-11-01","2029-11-01","2026-04-01",34,[730,731,732],"Gastric Adenocarcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[734,735,432,431,736,737,738],"RP2","5-Fluorouracil","Docetaxel","Pegfilgrastim","Filgrastim",{"trials":740,"activeCount":142},[],{"trials":742,"activeCount":142},[],{"trials":744,"activeCount":142},[],{"intervention":746,"totalTrials":500,"cells":747},"Avelumab",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":762,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":749,"activeCount":142},[],{"trials":751,"activeCount":142},[752],{"nctId":753,"briefTitle":754,"status":279,"phases":755,"primaryCompletion":756,"completion":757,"start":758,"enrollment":198,"conditions":759,"interventions":761},"NCT03483883","Avelumab\u002FGemcitabine in Sarcomatoid RCC",[88],"2020-07-22","2021-02-10","2018-03-19",[760],"Metastatic sRCC",[746,498],{"trials":763,"activeCount":9,"soonestReadout":768},[764],{"nctId":765,"briefTitle":766,"status":100,"phases":767,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":773},"NCT04841148","Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer",[89],"2027-07","2028-05","2021-06-01",96,[15],[774,746,775],"HCQ","Palbociclib",{"trials":777,"activeCount":142},[],{"trials":779,"activeCount":142},[],{"trials":781,"activeCount":142},[],{"intervention":432,"totalTrials":500,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":785,"activeCount":142},[],{"trials":787,"activeCount":142},[],{"trials":789,"activeCount":9,"soonestReadout":725},[790,794],{"nctId":419,"briefTitle":420,"status":114,"phases":791,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":792,"interventions":793},[88,89],[426,427,428,429],[42,431,432,433,433,434],{"nctId":721,"briefTitle":722,"status":723,"phases":795,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":796,"interventions":797},[89],[730,731,732],[734,735,432,431,736,737,738],{"trials":799,"activeCount":142},[],{"trials":801,"activeCount":142},[],{"trials":803,"activeCount":142},[],{"intervention":433,"totalTrials":500,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":807,"activeCount":142},[],{"trials":809,"activeCount":142},[],{"trials":811,"activeCount":9,"soonestReadout":725},[812,816],{"nctId":419,"briefTitle":420,"status":114,"phases":813,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":814,"interventions":815},[88,89],[426,427,428,429],[42,431,432,433,433,434],{"nctId":721,"briefTitle":722,"status":723,"phases":817,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":818,"interventions":819},[89],[730,731,732],[734,735,432,431,736,737,738],{"trials":821,"activeCount":142},[],{"trials":823,"activeCount":142},[],{"trials":825,"activeCount":142},[],{"intervention":443,"totalTrials":500,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":840,"PHASE3":846,"PHASE4":848,"NA":850},{"trials":829,"activeCount":142},[],{"trials":831,"activeCount":142},[832],{"nctId":833,"briefTitle":834,"status":114,"phases":835,"primaryCompletion":836,"completion":836,"start":423,"enrollment":716,"conditions":837,"interventions":839},"NCT01548807","Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy",[88],"2017-01-04",[838],"Prostate Cancer Patients With Detectable PSA Following Prostatectomy",[443],{"trials":841,"activeCount":9,"soonestReadout":41},[842],{"nctId":39,"briefTitle":40,"status":194,"phases":843,"primaryCompletion":41,"completion":437,"start":438,"enrollment":439,"conditions":844,"interventions":845},[89],[441],[42,443],{"trials":847,"activeCount":142},[],{"trials":849,"activeCount":142},[],{"trials":851,"activeCount":142},[],{"intervention":853,"totalTrials":500,"cells":854},"docetaxel",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":856,"activeCount":142},[],{"trials":858,"activeCount":142},[],{"trials":860,"activeCount":9,"soonestReadout":725},[861,871],{"nctId":862,"briefTitle":863,"status":114,"phases":864,"primaryCompletion":865,"completion":866,"start":867,"enrollment":22,"conditions":868,"interventions":869},"NCT00589420","Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy",[89],"2010-02-02","2011-02-02","2007-07-27",[24],[853,870],"sorafenib tosylate",{"nctId":721,"briefTitle":722,"status":723,"phases":872,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":873,"interventions":874},[89],[730,731,732],[734,735,432,431,736,737,738],{"trials":876,"activeCount":142},[],{"trials":878,"activeCount":142},[],{"trials":880,"activeCount":142},[],{"intervention":774,"totalTrials":500,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":901,"PHASE4":903,"NA":905},{"trials":884,"activeCount":142},[],{"trials":886,"activeCount":142},[],{"trials":888,"activeCount":9,"soonestReadout":768},[889,893],{"nctId":765,"briefTitle":766,"status":100,"phases":890,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":891,"interventions":892},[89],[15],[774,746,775],{"nctId":894,"briefTitle":895,"status":279,"phases":896,"primaryCompletion":897,"completion":898,"start":364,"enrollment":412,"conditions":899,"interventions":900},"NCT02013778","Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC",[88,89],"2018-11","2019-02",[550],[774],{"trials":902,"activeCount":142},[],{"trials":904,"activeCount":142},[],{"trials":906,"activeCount":142},[],{"intervention":775,"totalTrials":500,"cells":908},{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":929,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":910,"activeCount":142},[],{"trials":912,"activeCount":142},[913],{"nctId":914,"briefTitle":915,"status":114,"phases":916,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":926},"NCT03685331","HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",[88],"2025-08-01","2025-12-01","2020-10-15",9,[922,923,607,924,925],"Metastatic Breast Cancer","Locally Advanced Breast Cancer","BRCA2 Mutation","BRCA1 Mutation",[775,927,928],"Olaparib","Fulvestrant",{"trials":930,"activeCount":9,"soonestReadout":768},[931],{"nctId":765,"briefTitle":766,"status":100,"phases":932,"primaryCompletion":768,"completion":769,"start":770,"enrollment":771,"conditions":933,"interventions":934},[89],[15],[774,746,775],{"trials":936,"activeCount":142},[],{"trials":938,"activeCount":142},[],{"trials":940,"activeCount":142},[],{"intervention":475,"totalTrials":500,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":944,"activeCount":142},[],{"trials":946,"activeCount":142},[],{"trials":948,"activeCount":9,"soonestReadout":469},[949,953],{"nctId":544,"briefTitle":545,"status":279,"phases":950,"primaryCompletion":547,"completion":547,"start":548,"enrollment":508,"conditions":951,"interventions":952},[89],[550],[475,85],{"nctId":466,"briefTitle":467,"status":100,"phases":954,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":955,"interventions":956},[89],[15],[475,42],{"trials":958,"activeCount":142},[],{"trials":960,"activeCount":142},[],{"trials":962,"activeCount":142},[],{"intervention":964,"totalTrials":500,"cells":965},"filgrastim",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":967,"activeCount":142},[],{"trials":969,"activeCount":142},[],{"trials":971,"activeCount":9,"soonestReadout":725},[972,984],{"nctId":973,"briefTitle":974,"status":114,"phases":975,"primaryCompletion":976,"completion":976,"start":977,"enrollment":366,"conditions":978,"interventions":980},"NCT00002592","Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia",[89],"2002-08","1993-06",[979],"Leukemia",[981,964,982,983],"c-myb antisense oligonucleotide G4460","busulfan","cyclophosphamide",{"nctId":721,"briefTitle":722,"status":723,"phases":985,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":986,"interventions":987},[89],[730,731,732],[734,735,432,431,736,737,738],{"trials":989,"activeCount":142},[],{"trials":991,"activeCount":142},[],{"trials":993,"activeCount":142},[],{"intervention":172,"totalTrials":9,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":142},[],{"trials":999,"activeCount":142},[],{"trials":1001,"activeCount":9,"soonestReadout":165},[1002],{"nctId":162,"briefTitle":163,"status":100,"phases":1003,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":1004,"interventions":1005},[89],[170],[47,172],{"trials":1007,"activeCount":142},[],{"trials":1009,"activeCount":142},[],{"trials":1011,"activeCount":142},[],{"intervention":617,"totalTrials":9,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1015,"activeCount":142},[],{"trials":1017,"activeCount":142},[],{"trials":1019,"activeCount":9,"soonestReadout":66},[1020],{"nctId":64,"briefTitle":65,"status":100,"phases":1021,"primaryCompletion":66,"completion":66,"start":614,"enrollment":119,"conditions":1022,"interventions":1023},[89],[223],[67,568,617],{"trials":1025,"activeCount":142},[],{"trials":1027,"activeCount":142},[],{"trials":1029,"activeCount":142},[],{"intervention":1031,"totalTrials":9,"cells":1032},"Epcoritamab",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1034,"activeCount":142},[],{"trials":1036,"activeCount":142},[],{"trials":1038,"activeCount":9,"soonestReadout":1043},[1039],{"nctId":1040,"briefTitle":1041,"status":100,"phases":1042,"primaryCompletion":1043,"completion":469,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1052},"NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas",[89],"2027-10","2024-09-24",31,[1047,1048,1049,1050,1051],"Lymphoma, Non-Hodgkin","Relapsed Diffuse Large B Cell Lymphoma","Refractory Diffuse Large B-cell Lymphoma","High-grade B-cell Lymphoma","Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",[1031],{"trials":1054,"activeCount":142},[],{"trials":1056,"activeCount":142},[],{"trials":1058,"activeCount":142},[],{"intervention":1060,"totalTrials":9,"cells":1061},"XmAb20717",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1063,"activeCount":142},[],{"trials":1065,"activeCount":142},[],{"trials":1067,"activeCount":9,"soonestReadout":1072},[1068],{"nctId":1069,"briefTitle":1070,"status":194,"phases":1071,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":168,"conditions":1074,"interventions":1076},"NCT05297903","XmAb20717 in Advanced Biliary Tract Cancers",[89],"2026-12-02","2022-04-11",[1075],"Biliary Tract Cancer",[1060],{"trials":1078,"activeCount":142},[],{"trials":1080,"activeCount":142},[],{"trials":1082,"activeCount":142},[],{"intervention":1084,"totalTrials":9,"cells":1085},"18F-Fluoroestradiol",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1087,"activeCount":142},[],{"trials":1089,"activeCount":142},[],{"trials":1091,"activeCount":9,"soonestReadout":1096},[1092],{"nctId":1093,"briefTitle":1094,"status":100,"phases":1095,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":104,"conditions":1099,"interventions":1101},"NCT05916196","[18F]FES PET\u002F.CT in Uterine Cancer",[89],"2026-08-01","2027-08-01","2024-04-05",[1100],"Uterine Cancer",[1084],{"trials":1103,"activeCount":142},[],{"trials":1105,"activeCount":142},[],{"trials":1107,"activeCount":142},[],{"intervention":72,"totalTrials":9,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1111,"activeCount":142},[],{"trials":1113,"activeCount":142},[],{"trials":1115,"activeCount":9,"soonestReadout":71},[1116],{"nctId":69,"briefTitle":70,"status":100,"phases":1117,"primaryCompletion":71,"completion":71,"start":1118,"enrollment":1119,"conditions":1120,"interventions":1123},[89],"2021-10-07",70,[1121,1122],"Neuroendocrine Tumor Grade 2","Neuroendocrine Tumors",[72,1124,1125],"Temozolomide Oral Product","transarterial radioembolization",{"trials":1127,"activeCount":142},[],{"trials":1129,"activeCount":142},[],{"trials":1131,"activeCount":142},[],{"intervention":1124,"totalTrials":9,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1144,"PHASE4":1146,"NA":1148},{"trials":1135,"activeCount":142},[],{"trials":1137,"activeCount":142},[],{"trials":1139,"activeCount":9,"soonestReadout":71},[1140],{"nctId":69,"briefTitle":70,"status":100,"phases":1141,"primaryCompletion":71,"completion":71,"start":1118,"enrollment":1119,"conditions":1142,"interventions":1143},[89],[1121,1122],[72,1124,1125],{"trials":1145,"activeCount":142},[],{"trials":1147,"activeCount":142},[],{"trials":1149,"activeCount":142},[],{"intervention":1125,"totalTrials":9,"cells":1151},{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1153,"activeCount":142},[],{"trials":1155,"activeCount":142},[],{"trials":1157,"activeCount":9,"soonestReadout":71},[1158],{"nctId":69,"briefTitle":70,"status":100,"phases":1159,"primaryCompletion":71,"completion":71,"start":1118,"enrollment":1119,"conditions":1160,"interventions":1161},[89],[1121,1122],[72,1124,1125],{"trials":1163,"activeCount":142},[],{"trials":1165,"activeCount":142},[],{"trials":1167,"activeCount":142},[],{"intervention":1169,"totalTrials":9,"cells":1170},"Photofrin 2.0 mg\u002Fkg",{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1172,"activeCount":142},[],{"trials":1174,"activeCount":142},[],{"trials":1176,"activeCount":9,"soonestReadout":1181},[1177],{"nctId":1178,"briefTitle":1179,"status":194,"phases":1180,"primaryCompletion":1181,"completion":469,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1186},"NCT02153229","Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma",[89],"2026-12-16","2014-06-02",52,[1185],"Epitheliod Malignant Pleural Mesothelioma",[1169],{"trials":1188,"activeCount":142},[],{"trials":1190,"activeCount":142},[],{"trials":1192,"activeCount":142},[],{"intervention":1194,"totalTrials":9,"cells":1195},"Atezolizumab",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1212,"PHASE4":1214,"NA":1216},{"trials":1197,"activeCount":142},[],{"trials":1199,"activeCount":142},[],{"trials":1201,"activeCount":9,"soonestReadout":1206},[1202],{"nctId":1203,"briefTitle":1204,"status":100,"phases":1205,"primaryCompletion":1206,"completion":165,"start":1207,"enrollment":580,"conditions":1208,"interventions":1210},"NCT04691817","Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy",[88,89],"2026-12","2023-07-25",[1209],"Lung Cancer, Nonsmall Cell",[1194,1211],"Tocilizumab",{"trials":1213,"activeCount":142},[],{"trials":1215,"activeCount":142},[],{"trials":1217,"activeCount":142},[],{"intervention":1211,"totalTrials":9,"cells":1219},{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1230,"PHASE4":1232,"NA":1234},{"trials":1221,"activeCount":142},[],{"trials":1223,"activeCount":142},[],{"trials":1225,"activeCount":9,"soonestReadout":1206},[1226],{"nctId":1203,"briefTitle":1204,"status":100,"phases":1227,"primaryCompletion":1206,"completion":165,"start":1207,"enrollment":580,"conditions":1228,"interventions":1229},[88,89],[1209],[1194,1211],{"trials":1231,"activeCount":142},[],{"trials":1233,"activeCount":142},[],{"trials":1235,"activeCount":142},[],{"intervention":335,"totalTrials":9,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1239,"activeCount":142},[],{"trials":1241,"activeCount":142},[],{"trials":1243,"activeCount":9,"soonestReadout":328},[1244],{"nctId":325,"briefTitle":326,"status":100,"phases":1245,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1246,"interventions":1247},[89],[333],[52,335,270],{"trials":1249,"activeCount":142},[],{"trials":1251,"activeCount":142},[],{"trials":1253,"activeCount":142},[],{"intervention":1255,"totalTrials":9,"cells":1256},"mosunetuzumab",{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1258,"activeCount":142},[],{"trials":1260,"activeCount":142},[],{"trials":1262,"activeCount":9,"soonestReadout":310},[1263],{"nctId":1264,"briefTitle":1265,"status":100,"phases":1266,"primaryCompletion":310,"completion":1267,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1273},"NCT04889716","CAR-T Followed by Bispecific Antibodies",[89],"2028-12-31","2021-11-05",23,[1271,1272],"Large B-cell Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma",[1255,1274,1275],"glofitamab","obinutuzumab",{"trials":1277,"activeCount":142},[],{"trials":1279,"activeCount":142},[],{"trials":1281,"activeCount":142},[],{"intervention":1274,"totalTrials":9,"cells":1283},{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1285,"activeCount":142},[],{"trials":1287,"activeCount":142},[],{"trials":1289,"activeCount":9,"soonestReadout":310},[1290],{"nctId":1264,"briefTitle":1265,"status":100,"phases":1291,"primaryCompletion":310,"completion":1267,"start":1268,"enrollment":1269,"conditions":1292,"interventions":1293},[89],[1271,1272],[1255,1274,1275],{"trials":1295,"activeCount":142},[],{"trials":1297,"activeCount":142},[],{"trials":1299,"activeCount":142},[],{"intervention":1275,"totalTrials":9,"cells":1301},{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1312,"PHASE4":1314,"NA":1316},{"trials":1303,"activeCount":142},[],{"trials":1305,"activeCount":142},[],{"trials":1307,"activeCount":9,"soonestReadout":310},[1308],{"nctId":1264,"briefTitle":1265,"status":100,"phases":1309,"primaryCompletion":310,"completion":1267,"start":1268,"enrollment":1269,"conditions":1310,"interventions":1311},[89],[1271,1272],[1255,1274,1275],{"trials":1313,"activeCount":142},[],{"trials":1315,"activeCount":142},[],{"trials":1317,"activeCount":142},[],{"intervention":734,"totalTrials":9,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1321,"activeCount":142},[],{"trials":1323,"activeCount":142},[],{"trials":1325,"activeCount":9,"soonestReadout":725},[1326],{"nctId":721,"briefTitle":722,"status":723,"phases":1327,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":1328,"interventions":1329},[89],[730,731,732],[734,735,432,431,736,737,738],{"trials":1331,"activeCount":142},[],{"trials":1333,"activeCount":142},[],{"trials":1335,"activeCount":142},[],{"intervention":737,"totalTrials":9,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1339,"activeCount":142},[],{"trials":1341,"activeCount":142},[],{"trials":1343,"activeCount":9,"soonestReadout":725},[1344],{"nctId":721,"briefTitle":722,"status":723,"phases":1345,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":1346,"interventions":1347},[89],[730,731,732],[734,735,432,431,736,737,738],{"trials":1349,"activeCount":142},[],{"trials":1351,"activeCount":142},[],{"trials":1353,"activeCount":142},[],{"intervention":57,"totalTrials":252,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1366,"PHASE2":1392,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1357,"activeCount":142},[1358],{"nctId":1359,"briefTitle":1360,"status":279,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":198,"conditions":1364,"interventions":1365},"NCT03492164","In Vivo PARP-1 Expression With 18F-FTT PET\u002FCT in Pancreatic Cancer",[87],"2024-06-11","2018-03-20",[519],[57],{"trials":1367,"activeCount":336,"soonestReadout":56},[1368,1378,1383],{"nctId":1369,"briefTitle":1370,"status":100,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1377},"NCT02637934","Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET\u002FCT",[88],"2026-10","2016-01-14",35,[1376],"Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[57],{"nctId":54,"briefTitle":55,"status":194,"phases":1379,"primaryCompletion":56,"completion":56,"start":1380,"enrollment":104,"conditions":1381,"interventions":1382},[88],"2017-02-22",[15],[57],{"nctId":1384,"briefTitle":1385,"status":100,"phases":1386,"primaryCompletion":165,"completion":165,"start":1387,"enrollment":209,"conditions":1388,"interventions":1391},"NCT07114939","FTT PET\u002FCT in Pancreatic Neuroendocrine Tumors",[88],"2025-10-01",[1389,1390],"Neuroendocrine Carcinoma Metastatic","Pancreatic Tumors",[57],{"trials":1393,"activeCount":142},[],{"trials":1395,"activeCount":142},[],{"trials":1397,"activeCount":142},[],{"trials":1399,"activeCount":9,"soonestReadout":1404},[1400],{"nctId":1401,"briefTitle":1402,"status":100,"phases":1403,"primaryCompletion":1404,"completion":1404,"start":1405,"enrollment":104,"conditions":1406,"interventions":1408},"NCT05242744","FTT PET\u002FCT in Metastatic Prostate Cancer",[],"2026-07","2023-03-01",[1407],"Prostate Cancer Metastatic",[57],{"intervention":499,"totalTrials":198,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1434,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1412,"activeCount":142},[],{"trials":1414,"activeCount":9,"soonestReadout":1206},[1415,1424],{"nctId":1416,"briefTitle":1417,"status":114,"phases":1418,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":95,"conditions":1421,"interventions":1423},"NCT02030860","A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer",[88],"2015-12","2014-01",[1422],"Adenocarcinoma of the Pancreas",[522,499,498],{"nctId":1425,"briefTitle":1426,"status":194,"phases":1427,"primaryCompletion":1206,"completion":1206,"start":1428,"enrollment":1429,"conditions":1430,"interventions":1433},"NCT02207465","A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer",[88],"2014-07",42,[1431,1432],"Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy","Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy",[499],{"trials":1435,"activeCount":142},[1436,1447,1457,1468],{"nctId":1437,"briefTitle":1438,"status":114,"phases":1439,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":221,"conditions":1443,"interventions":1445},"NCT01839799","A Randomized Phase II\u002FGenomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma",[89],"2017-04","2017-07","2013-04",[1444],"Pancreatic Adenocarcinoma",[498,499,1446],"FOLFIRINOX",{"nctId":1448,"briefTitle":1449,"status":114,"phases":1450,"primaryCompletion":1451,"completion":1451,"start":1452,"enrollment":1453,"conditions":1454,"interventions":1456},"NCT02303977","Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy",[89],"2020-04-30","2015-06-26",37,[1455],"Patients With Stage IV or Recurrent Adenocarcinoma of the Lung",[499,498],{"nctId":1458,"briefTitle":1459,"status":138,"phases":1460,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":142,"conditions":1464,"interventions":1466},"NCT04134468","MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma",[89],"2021-02-11","2022-11-11","2020-01",[1465],"Pancreatic Ductal Adenocarcinoma",[1467,499,498],"Pegvorhyaluronidase alfa",{"nctId":488,"briefTitle":489,"status":114,"phases":1469,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":1470,"interventions":1471},[88,89],[495,496],[42,498,499],{"trials":1473,"activeCount":142},[],{"trials":1475,"activeCount":142},[],{"trials":1477,"activeCount":142},[],{"intervention":1479,"totalTrials":9,"cells":1480},"SBRT + atezolizumab and bevacizumab",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1482,"activeCount":142},[],{"trials":1484,"activeCount":9,"soonestReadout":237},[1485],{"nctId":1486,"briefTitle":1487,"status":100,"phases":1488,"primaryCompletion":237,"completion":237,"start":1489,"enrollment":22,"conditions":1490,"interventions":1491},"NCT05488522","SBRT With Atezo\u002FBev for HCC",[88],"2022-09-01",[550],[1479],{"trials":1493,"activeCount":142},[],{"trials":1495,"activeCount":142},[],{"trials":1497,"activeCount":142},[],{"trials":1499,"activeCount":142},[],{"intervention":1501,"totalTrials":9,"cells":1502},"INO-5401",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1504,"activeCount":142},[],{"trials":1506,"activeCount":9,"soonestReadout":1206},[1507],{"nctId":1508,"briefTitle":1509,"status":194,"phases":1510,"primaryCompletion":1206,"completion":1511,"start":1512,"enrollment":472,"conditions":1513,"interventions":1515},"NCT04367675","INO 5401 Vaccination in BRCA1\u002F2 Mutation Carriers",[88],"2027-03","2021-04-20",[1514],"BRCA1\u002F2 Mutation",[1501,1516],"INO-9012",{"trials":1518,"activeCount":142},[],{"trials":1520,"activeCount":142},[],{"trials":1522,"activeCount":142},[],{"trials":1524,"activeCount":142},[],{"intervention":1516,"totalTrials":9,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":142},[],{"trials":1530,"activeCount":9,"soonestReadout":1206},[1531],{"nctId":1508,"briefTitle":1509,"status":194,"phases":1532,"primaryCompletion":1206,"completion":1511,"start":1512,"enrollment":472,"conditions":1533,"interventions":1534},[88],[1514],[1501,1516],{"trials":1536,"activeCount":142},[],{"trials":1538,"activeCount":142},[],{"trials":1540,"activeCount":142},[],{"trials":1542,"activeCount":142},[],{"intervention":1544,"totalTrials":9,"cells":1545},"Vancomycin 125mg",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1547,"activeCount":142},[],{"trials":1549,"activeCount":9,"soonestReadout":1554},[1550],{"nctId":1551,"briefTitle":1552,"status":723,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1563},"NCT07478848","Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas",[88],"2029-01-01","2026-05-27",14,[1558,1559,1560,1561,1562],"Large B Cell Lymphoma","Non Hodgkin Lymphoma (NHL)","Diffuse Large B Cell Lymphoma (DLBCL)","Diffuse Large B Cell Lymphoma Refractory","Diffuse Large B Cell Lymphoma Relapsed",[1544,1564],"CAR-T",{"trials":1566,"activeCount":142},[],{"trials":1568,"activeCount":142},[],{"trials":1570,"activeCount":142},[],{"trials":1572,"activeCount":142},[],{"intervention":1564,"totalTrials":9,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1583,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1576,"activeCount":142},[],{"trials":1578,"activeCount":9,"soonestReadout":1554},[1579],{"nctId":1551,"briefTitle":1552,"status":723,"phases":1580,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1581,"interventions":1582},[88],[1558,1559,1560,1561,1562],[1544,1564],{"trials":1584,"activeCount":142},[],{"trials":1586,"activeCount":142},[],{"trials":1588,"activeCount":142},[],{"trials":1590,"activeCount":142},[],{"intervention":134,"totalTrials":9,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1594,"activeCount":142},[],{"trials":1596,"activeCount":9,"soonestReadout":127},[1597],{"nctId":124,"briefTitle":125,"status":100,"phases":1598,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":1599,"interventions":1600},[88],[131],[47,133,134],{"trials":1602,"activeCount":142},[],{"trials":1604,"activeCount":142},[],{"trials":1606,"activeCount":142},[],{"trials":1608,"activeCount":142},[],{"intervention":1610,"totalTrials":9,"cells":1611},"Vancomycin",{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1613,"activeCount":142},[],{"trials":1615,"activeCount":9,"soonestReadout":310},[1616],{"nctId":1617,"briefTitle":1618,"status":100,"phases":1619,"primaryCompletion":310,"completion":1267,"start":1620,"enrollment":36,"conditions":1621,"interventions":1623},"NCT03546829","Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer",[88],"2019-03-05",[1622],"Early Stage Non-Small Cell Lung Cancer",[1610],{"trials":1625,"activeCount":142},[],{"trials":1627,"activeCount":142},[],{"trials":1629,"activeCount":142},[],{"trials":1631,"activeCount":142},[],{"intervention":1633,"totalTrials":9,"cells":1634},"Administration of Indocyanine Green (ICG) and Visualization of Tumor",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1650,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1636,"activeCount":142},[],{"trials":1638,"activeCount":9,"soonestReadout":1644},[1639],{"nctId":1640,"briefTitle":1641,"status":1642,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1649},"NCT05746104","Second Window Indocyanine Green for All Nervous System Tumors","ENROLLING_BY_INVITATION",[88],"2027-02-15","2023-03-31",105,[1648],"Nervous System Tumor",[1633],{"trials":1651,"activeCount":142},[],{"trials":1653,"activeCount":142},[],{"trials":1655,"activeCount":142},[],{"trials":1657,"activeCount":142},[],{"intervention":1659,"totalTrials":9,"cells":1660},"Fluoroglutamine [18F]F-GLN",{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1662,"activeCount":142},[],{"trials":1664,"activeCount":9,"soonestReadout":1206},[1665],{"nctId":1666,"briefTitle":1667,"status":100,"phases":1668,"primaryCompletion":1206,"completion":1206,"start":1669,"enrollment":366,"conditions":1670,"interventions":1671},"NCT03863457","[18F] F-GLN by PET\u002FCT in Breast Cancer",[88],"2019-04-05",[15],[1659],{"trials":1673,"activeCount":142},[],{"trials":1675,"activeCount":142},[],{"trials":1677,"activeCount":142},[],{"trials":1679,"activeCount":142},[],{"intervention":1681,"totalTrials":9,"cells":1682},"[F-18]-FAPI-74",{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1684,"activeCount":142},[],{"trials":1686,"activeCount":9,"soonestReadout":1691},[1687],{"nctId":1688,"briefTitle":1689,"status":100,"phases":1690,"primaryCompletion":1691,"completion":1691,"start":1692,"enrollment":1693,"conditions":1694,"interventions":1696},"NCT06413355","FAPI-74 PET\u002FCT in Adults With Fibrosis",[88],"2027-07-30","2024-07-16",45,[1695],"Fibrosis (Morphologic Abnormality)",[1681],{"trials":1698,"activeCount":142},[],{"trials":1700,"activeCount":142},[],{"trials":1702,"activeCount":142},[],{"trials":1704,"activeCount":142},[],{"intervention":1706,"totalTrials":412,"cells":1707},"cisplatin",{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1738,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1709,"activeCount":142},[],{"trials":1711,"activeCount":9,"soonestReadout":127},[1712,1716,1728],{"nctId":124,"briefTitle":125,"status":100,"phases":1713,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":1714,"interventions":1715},[88],[131],[47,133,134],{"nctId":1717,"briefTitle":1718,"status":114,"phases":1719,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":22,"conditions":1722,"interventions":1725},"NCT01042041","Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer",[88],"2010-12","2009-09",[550,1723,1724],"Liver Cancer","Localized Unresectable Liver Cancer",[870,1726,1706,1727],"doxorubicin hydrochloride","mitomycin C",{"nctId":1729,"briefTitle":1730,"status":114,"phases":1731,"primaryCompletion":1732,"completion":1732,"start":1733,"enrollment":198,"conditions":1734,"interventions":1736},"NCT02363829","A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)",[88],"2020-02-17","2015-02",[1735],"Uterine Cervix Cancer",[1737,133],"Nelfinavir",{"trials":1739,"activeCount":142},[1740,1751,1765,1775],{"nctId":1741,"briefTitle":1742,"status":114,"phases":1743,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":728,"conditions":1747,"interventions":1749},"NCT01076231","Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery",[88,89],"2016-12","2018-05-24","2010-01",[1748],"Stage IIIA Non-small Cell Lung Cancer",[1706,1750],"etoposide",{"nctId":1752,"briefTitle":1753,"status":138,"phases":1754,"primaryCompletion":1755,"completion":1756,"start":698,"enrollment":142,"conditions":1757,"interventions":1764},"NCT01019278","Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes",[89],"2011-08","2011-08-18",[1758,1759,1760,1761,1762,1763],"Cervical Cancer","Stage IB Cervical Cancer","Stage IIA Cervical Cancer","Stage IIB Cervical Cancer","Stage III Cervical Cancer","Stage IVA Cervical Cancer",[1706],{"nctId":1766,"briefTitle":1767,"status":279,"phases":1768,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1374,"conditions":1772,"interventions":1773},"NCT00003777","Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer",[89],"2001-04","2001-04-20","1998-12",[30],[1774,1706,704],"amifostine trihydrate",{"nctId":1776,"briefTitle":1777,"status":114,"phases":1778,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1781,"conditions":1782,"interventions":1783},"NCT00589056","Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery",[88,89],"2012-03","2007-06",55,[21],[1706,1750,1784,1785],"nelfinavir mesylate","protein expression analysis",{"trials":1787,"activeCount":142},[],{"trials":1789,"activeCount":142},[],{"trials":1791,"activeCount":142},[1792],{"nctId":1793,"briefTitle":1794,"status":279,"phases":1795,"primaryCompletion":1796,"completion":1744,"start":698,"enrollment":209,"conditions":1797,"interventions":1798},"NCT01016561","Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer",[92],"2012-07",[1758],[133],{"intervention":1800,"totalTrials":9,"cells":1801},"18F-FES",{"EARLY_PHASE1":1802,"PHASE1":1811,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1803,"activeCount":9,"soonestReadout":102},[1804],{"nctId":1805,"briefTitle":1806,"status":100,"phases":1807,"primaryCompletion":102,"completion":102,"start":1808,"enrollment":129,"conditions":1809,"interventions":1810},"NCT05659797","FES BPET-DBT in Newly Diagnosed Breast Cancer",[87],"2023-10-02",[15],[1800],{"trials":1812,"activeCount":142},[],{"trials":1814,"activeCount":142},[],{"trials":1816,"activeCount":142},[],{"trials":1818,"activeCount":142},[],{"trials":1820,"activeCount":142},[],{"intervention":108,"totalTrials":9,"cells":1822},{"EARLY_PHASE1":1823,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1824,"activeCount":9,"soonestReadout":76},[1825],{"nctId":74,"briefTitle":75,"status":100,"phases":1826,"primaryCompletion":76,"completion":102,"start":103,"enrollment":104,"conditions":1827,"interventions":1828},[87],[106],[47,108],{"trials":1830,"activeCount":142},[],{"trials":1832,"activeCount":142},[],{"trials":1834,"activeCount":142},[],{"trials":1836,"activeCount":142},[],{"trials":1838,"activeCount":142},[],{"intervention":1840,"totalTrials":9,"cells":1841},"Fluciclovine F18",{"EARLY_PHASE1":1842,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1843,"activeCount":9,"soonestReadout":1848},[1844],{"nctId":1845,"briefTitle":1846,"status":100,"phases":1847,"primaryCompletion":1848,"completion":237,"start":1849,"enrollment":95,"conditions":1850,"interventions":1852},"NCT06613841","Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma",[87],"2026-10-01","2025-05-01",[662,663,1851],"Glioblastoma Multiforme of Brain",[1840],{"trials":1854,"activeCount":142},[],{"trials":1856,"activeCount":142},[],{"trials":1858,"activeCount":142},[],{"trials":1860,"activeCount":142},[],{"trials":1862,"activeCount":142},[],{"intervention":1864,"totalTrials":9,"cells":1865},"Poly(ADP Ribose) Polymerase 1",{"EARLY_PHASE1":1866,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1867,"activeCount":9,"soonestReadout":1872},[1868],{"nctId":1869,"briefTitle":1870,"status":194,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":104,"conditions":1874,"interventions":1875},"NCT03334500","Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET\u002FCT) in Prostate Cancer",[87],"2027-02-11","2017-07-14",[24],[1864],{"trials":1877,"activeCount":142},[],{"trials":1879,"activeCount":142},[],{"trials":1881,"activeCount":142},[],{"trials":1883,"activeCount":142},[],{"trials":1885,"activeCount":142},[],{"intervention":1887,"totalTrials":9,"cells":1888},"CYTALUX™",{"EARLY_PHASE1":1889,"PHASE1":1903,"PHASE2":1905,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1890,"activeCount":9,"soonestReadout":1043},[1891],{"nctId":1892,"briefTitle":1893,"status":100,"phases":1894,"primaryCompletion":1043,"completion":1895,"start":1896,"enrollment":36,"conditions":1897,"interventions":1902},"NCT07278986","CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer",[87],"2029-02","2025-10-18",[1898,1899,1900,1901],"Endometrial Cancer","Near Infrared Fluorescence Imaging","CYTALUX (Pafolacianine) Injection","Planned Diagnostic Laparoscopies",[1887],{"trials":1904,"activeCount":142},[],{"trials":1906,"activeCount":142},[],{"trials":1908,"activeCount":142},[],{"trials":1910,"activeCount":142},[],{"trials":1912,"activeCount":142},[],{"intervention":1914,"totalTrials":9,"cells":1915},"Influenza vaccination",{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1917,"activeCount":142},[],{"trials":1919,"activeCount":142},[],{"trials":1921,"activeCount":142},[],{"trials":1923,"activeCount":142},[],{"trials":1925,"activeCount":142},[],{"trials":1927,"activeCount":9,"soonestReadout":1043},[1928],{"nctId":1929,"briefTitle":1930,"status":194,"phases":1931,"primaryCompletion":1043,"completion":1932,"start":1933,"enrollment":1934,"conditions":1935,"interventions":1937},"NCT06605625","Vaccine Responses in Cancer",[],"2028-10","2022-11-04",250,[1936],"Viral Vaccines",[1914,1938,1939],"SARS-CoV-2 vaccine","Zoster Vaccine Recombinant",{"intervention":1938,"totalTrials":9,"cells":1941},{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1943,"activeCount":142},[],{"trials":1945,"activeCount":142},[],{"trials":1947,"activeCount":142},[],{"trials":1949,"activeCount":142},[],{"trials":1951,"activeCount":142},[],{"trials":1953,"activeCount":9,"soonestReadout":1043},[1954],{"nctId":1929,"briefTitle":1930,"status":194,"phases":1955,"primaryCompletion":1043,"completion":1932,"start":1933,"enrollment":1934,"conditions":1956,"interventions":1957},[],[1936],[1914,1938,1939],{"intervention":1939,"totalTrials":9,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1961,"activeCount":142},[],{"trials":1963,"activeCount":142},[],{"trials":1965,"activeCount":142},[],{"trials":1967,"activeCount":142},[],{"trials":1969,"activeCount":142},[],{"trials":1971,"activeCount":9,"soonestReadout":1043},[1972],{"nctId":1929,"briefTitle":1930,"status":194,"phases":1973,"primaryCompletion":1043,"completion":1932,"start":1933,"enrollment":1934,"conditions":1974,"interventions":1975},[],[1936],[1914,1938,1939],{"intervention":62,"totalTrials":9,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1986,"NA":1988},{"trials":1979,"activeCount":142},[],{"trials":1981,"activeCount":142},[],{"trials":1983,"activeCount":142},[],{"trials":1985,"activeCount":142},[],{"trials":1987,"activeCount":142},[],{"trials":1989,"activeCount":9,"soonestReadout":61},[1990],{"nctId":59,"briefTitle":60,"status":194,"phases":1991,"primaryCompletion":61,"completion":76,"start":1992,"enrollment":424,"conditions":1993,"interventions":1994},[],"2019-10-28",[925,924],[62],{"intervention":1996,"totalTrials":9,"cells":1997},"Fesoterodine",{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2004,"PHASE4":2006,"NA":2017},{"trials":1999,"activeCount":142},[],{"trials":2001,"activeCount":142},[],{"trials":2003,"activeCount":142},[],{"trials":2005,"activeCount":142},[],{"trials":2007,"activeCount":142},[2008],{"nctId":2009,"briefTitle":2010,"status":114,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":2013,"enrollment":336,"conditions":2014,"interventions":2016},"NCT01661166","A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder\u002FDetrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy",[91],"2013-04-15","2012-01",[2015],"Prostate Adenocarcinoma",[1996],{"trials":2018,"activeCount":142},[],{"intervention":498,"totalTrials":412,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2027,"PHASE2":2047,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2022,"activeCount":142},[2023],{"nctId":513,"briefTitle":514,"status":279,"phases":2024,"primaryCompletion":516,"completion":516,"start":517,"enrollment":336,"conditions":2025,"interventions":2026},[87],[519],[85,521,498,522],{"trials":2028,"activeCount":142},[2029,2033,2037],{"nctId":753,"briefTitle":754,"status":279,"phases":2030,"primaryCompletion":756,"completion":757,"start":758,"enrollment":198,"conditions":2031,"interventions":2032},[88],[760],[746,498],{"nctId":1416,"briefTitle":1417,"status":114,"phases":2034,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":95,"conditions":2035,"interventions":2036},[88],[1422],[522,499,498],{"nctId":2038,"briefTitle":2039,"status":114,"phases":2040,"primaryCompletion":897,"completion":897,"start":2041,"enrollment":716,"conditions":2042,"interventions":2043},"NCT02588443","Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma",[88],"2015-10",[519],[2044,2045,2046],"RO70097890","nab-paclitaxel","gemcitabine",{"trials":2048,"activeCount":142},[2049,2053,2057,2061],{"nctId":1437,"briefTitle":1438,"status":114,"phases":2050,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":221,"conditions":2051,"interventions":2052},[89],[1444],[498,499,1446],{"nctId":1448,"briefTitle":1449,"status":114,"phases":2054,"primaryCompletion":1451,"completion":1451,"start":1452,"enrollment":1453,"conditions":2055,"interventions":2056},[89],[1455],[499,498],{"nctId":1458,"briefTitle":1459,"status":138,"phases":2058,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":142,"conditions":2059,"interventions":2060},[89],[1465],[1467,499,498],{"nctId":488,"briefTitle":489,"status":114,"phases":2062,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":2063,"interventions":2064},[88,89],[495,496],[42,498,499],{"trials":2066,"activeCount":142},[],{"trials":2068,"activeCount":142},[],{"trials":2070,"activeCount":142},[],{"intervention":434,"totalTrials":198,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2110,"PHASE3":2124,"PHASE4":2126,"NA":2128},{"trials":2074,"activeCount":142},[],{"trials":2076,"activeCount":142},[2077,2087,2096],{"nctId":2078,"briefTitle":2079,"status":114,"phases":2080,"primaryCompletion":2081,"completion":2082,"start":2083,"enrollment":19,"conditions":2084,"interventions":2085},"NCT01625936","CRLX101 Plus Bevacizumab in Advanced RCC",[88],"2017-07-01","2018-07-16","2012-06",[106],[2086,434],"CRLX101",{"nctId":2088,"briefTitle":2089,"status":279,"phases":2090,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":500,"conditions":2093,"interventions":2094},"NCT03573986","Pilot Study of 18F-FMISO PET\u002FCT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment",[88],"2020-01-14","2018-04-18",[663],[2095,434],"[18F]fluoromisonidazole",{"nctId":2097,"briefTitle":2098,"status":279,"phases":2099,"primaryCompletion":2041,"completion":2100,"start":579,"enrollment":22,"conditions":2101,"interventions":2105},"NCT01312376","Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer",[88],"2019-01",[2102,2103,2104],"Ovarian Carcinoma","Fallopian Tube Cancer","Primary Peritoneal Cancer",[2106,434,2107,2108,2109],"OC-DC vaccine","cyclophosphamide 300 mg\u002Fm2\u002Fd for 3 days","fludarabine 30 mg\u002Fm2\u002Fd for 3 days","ex vivo CD3\u002FCD28-costimulated vaccine-primed peripheral blood autologous T cells",{"trials":2111,"activeCount":142},[2112,2116,2120],{"nctId":695,"briefTitle":696,"status":279,"phases":2113,"primaryCompletion":698,"completion":699,"start":700,"enrollment":252,"conditions":2114,"interventions":2115},[89],[33],[703,704,705,706],{"nctId":419,"briefTitle":420,"status":114,"phases":2117,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":2118,"interventions":2119},[88,89],[426,427,428,429],[42,431,432,433,433,434],{"nctId":712,"briefTitle":713,"status":114,"phases":2121,"primaryCompletion":482,"completion":482,"start":715,"enrollment":716,"conditions":2122,"interventions":2123},[89],[519],[703,704,719,706],{"trials":2125,"activeCount":142},[],{"trials":2127,"activeCount":142},[],{"trials":2129,"activeCount":142},[],{"intervention":704,"totalTrials":336,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2150,"PHASE4":2152,"NA":2154},{"trials":2133,"activeCount":142},[],{"trials":2135,"activeCount":142},[],{"trials":2137,"activeCount":142},[2138,2142,2146],{"nctId":695,"briefTitle":696,"status":279,"phases":2139,"primaryCompletion":698,"completion":699,"start":700,"enrollment":252,"conditions":2140,"interventions":2141},[89],[33],[703,704,705,706],{"nctId":712,"briefTitle":713,"status":114,"phases":2143,"primaryCompletion":482,"completion":482,"start":715,"enrollment":716,"conditions":2144,"interventions":2145},[89],[519],[703,704,719,706],{"nctId":1766,"briefTitle":1767,"status":279,"phases":2147,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1374,"conditions":2148,"interventions":2149},[89],[30],[1774,1706,704],{"trials":2151,"activeCount":142},[],{"trials":2153,"activeCount":142},[],{"trials":2155,"activeCount":142},[],{"intervention":870,"totalTrials":336,"cells":2157},{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2166,"PHASE3":2183,"PHASE4":2185,"NA":2187},{"trials":2159,"activeCount":142},[],{"trials":2161,"activeCount":142},[2162],{"nctId":1717,"briefTitle":1718,"status":114,"phases":2163,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":22,"conditions":2164,"interventions":2165},[88],[550,1723,1724],[870,1726,1706,1727],{"trials":2167,"activeCount":142},[2168,2172],{"nctId":862,"briefTitle":863,"status":114,"phases":2169,"primaryCompletion":865,"completion":866,"start":867,"enrollment":22,"conditions":2170,"interventions":2171},[89],[24],[853,870],{"nctId":2173,"briefTitle":2174,"status":114,"phases":2175,"primaryCompletion":2176,"completion":2177,"start":2178,"enrollment":2179,"conditions":2180,"interventions":2182},"NCT00602576","Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma",[89],"2008-12-21","2009-07-26","2005-01-01",169,[2181],"Melanoma (Skin)",[870,403],{"trials":2184,"activeCount":142},[],{"trials":2186,"activeCount":142},[],{"trials":2188,"activeCount":142},[],{"intervention":403,"totalTrials":336,"cells":2190},{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2207,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2192,"activeCount":142},[],{"trials":2194,"activeCount":142},[2195,2203],{"nctId":2196,"briefTitle":2197,"status":279,"phases":2198,"primaryCompletion":397,"completion":1419,"start":2199,"enrollment":95,"conditions":2200,"interventions":2202},"NCT00915694","Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme",[88],"2009-04",[2201],"Brain and Central Nervous System Tumors",[1784,403],{"nctId":394,"briefTitle":395,"status":114,"phases":2204,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":2205,"interventions":2206},[88],[368],[370,403,404,405],{"trials":2208,"activeCount":142},[2209],{"nctId":2173,"briefTitle":2174,"status":114,"phases":2210,"primaryCompletion":2176,"completion":2177,"start":2178,"enrollment":2179,"conditions":2211,"interventions":2212},[89],[2181],[870,403],{"trials":2214,"activeCount":142},[],{"trials":2216,"activeCount":142},[],{"trials":2218,"activeCount":142},[],{"intervention":1737,"totalTrials":336,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2237,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2222,"activeCount":142},[],{"trials":2224,"activeCount":142},[2225,2233],{"nctId":2226,"briefTitle":2227,"status":114,"phases":2228,"primaryCompletion":2229,"completion":2229,"start":2199,"enrollment":1045,"conditions":2230,"interventions":2232},"NCT01020292","A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma",[88],"2017-12",[2231],"Glioma",[1737],{"nctId":1729,"briefTitle":1730,"status":114,"phases":2234,"primaryCompletion":1732,"completion":1732,"start":1733,"enrollment":198,"conditions":2235,"interventions":2236},[88],[1735],[1737,133],{"trials":2238,"activeCount":142},[2239],{"nctId":2240,"briefTitle":2241,"status":279,"phases":2242,"primaryCompletion":2243,"completion":116,"start":2244,"enrollment":508,"conditions":2245,"interventions":2247},"NCT01108666","Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)",[89],"2018-07","2010-03",[2246],"Non Small Cell Lung Cancer",[1737],{"trials":2249,"activeCount":142},[],{"trials":2251,"activeCount":142},[],{"trials":2253,"activeCount":142},[],{"intervention":2255,"totalTrials":500,"cells":2256},"Lenalidomide",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2258,"activeCount":142},[],{"trials":2260,"activeCount":142},[],{"trials":2262,"activeCount":142},[2263,2272],{"nctId":2264,"briefTitle":2265,"status":114,"phases":2266,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":412,"conditions":2270,"interventions":2271},"NCT01575860","Maintenance Lenalidomide in Lymphoma",[88,89],"2018-05-30","2022-10-31","2012-04",[191],[2255],{"nctId":2273,"briefTitle":2274,"status":114,"phases":2275,"primaryCompletion":2276,"completion":2277,"start":2278,"enrollment":424,"conditions":2279,"interventions":2287},"NCT00783367","Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",[89],"2012-11-14","2020-11-23","2008-07",[2280,2281,2282,2283,2284,2285,2286],"Follicular Lymphoma","Marginal Zone B-Cell Lymphoma","MALT Lymphoma","Lymphoma of Mucosa-Associated Lymphoid Tissue","Lymphoma, Small Lymphocytic","Waldenstrom Macroglobulinemia","Mantle-Cell Lymphoma",[2255,2288,2289],"Dexamethasone","Rituximab",{"trials":2291,"activeCount":142},[],{"trials":2293,"activeCount":142},[],{"trials":2295,"activeCount":142},[],{"intervention":2297,"totalTrials":500,"cells":2298},"Indocyanine Green",{"EARLY_PHASE1":2299,"PHASE1":2311,"PHASE2":2313,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2300,"activeCount":142},[2301],{"nctId":2302,"briefTitle":2303,"status":114,"phases":2304,"primaryCompletion":2305,"completion":2305,"start":397,"enrollment":36,"conditions":2306,"interventions":2310},"NCT01796041","Intraoperative Imaging of Breast Cancer With Indocyanine Green",[87],"2016-11-09",[2307,2308,2309],"Invasive Ductal Carcinoma","Invasive Lobular Carcinoma","Ductal Carcinoma",[2297],{"trials":2312,"activeCount":142},[],{"trials":2314,"activeCount":142},[2315],{"nctId":2316,"briefTitle":2317,"status":114,"phases":2318,"primaryCompletion":2319,"completion":2320,"start":2321,"enrollment":2322,"conditions":2323,"interventions":2325},"NCT02710240","Indocyanine Green for Central Nervous System Tumors",[88,89],"2020-02-04","2020-04-02","2015-06-10",336,[2324],"Suspected Central Nervous System Tumors",[2297],{"trials":2327,"activeCount":142},[],{"trials":2329,"activeCount":142},[],{"trials":2331,"activeCount":142},[],{"intervention":1784,"totalTrials":500,"cells":2333},{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2342,"PHASE3":2348,"PHASE4":2350,"NA":2352},{"trials":2335,"activeCount":142},[],{"trials":2337,"activeCount":142},[2338],{"nctId":2196,"briefTitle":2197,"status":279,"phases":2339,"primaryCompletion":397,"completion":1419,"start":2199,"enrollment":95,"conditions":2340,"interventions":2341},[88],[2201],[1784,403],{"trials":2343,"activeCount":142},[2344],{"nctId":1776,"briefTitle":1777,"status":114,"phases":2345,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1781,"conditions":2346,"interventions":2347},[88,89],[21],[1706,1750,1784,1785],{"trials":2349,"activeCount":142},[],{"trials":2351,"activeCount":142},[],{"trials":2353,"activeCount":142},[],{"intervention":2355,"totalTrials":500,"cells":2356},"Bexarotene",{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2370,"PHASE3":2382,"PHASE4":2384,"NA":2386},{"trials":2358,"activeCount":142},[],{"trials":2360,"activeCount":142},[2361],{"nctId":2362,"briefTitle":2363,"status":114,"phases":2364,"start":2365,"enrollment":312,"conditions":2366,"interventions":2369},"NCT00316030","Study of Bexarotene in Patients With Acute Myeloid Leukemia",[88],"2004-01",[2367,2368],"AML","Acute Myeloid Leukemia",[2355],{"trials":2371,"activeCount":142},[2372],{"nctId":2373,"briefTitle":2374,"status":279,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":2378,"enrollment":2379,"conditions":2380,"interventions":2381},"NCT00615784","Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia",[89],"2013-10-01","2013-11-08","2010-05-25",24,[2368],[2355],{"trials":2383,"activeCount":142},[],{"trials":2385,"activeCount":142},[],{"trials":2387,"activeCount":142},[],{"intervention":2389,"totalTrials":500,"cells":2390},"chemotherapy",{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2404,"PHASE3":2417,"PHASE4":2419,"NA":2421},{"trials":2392,"activeCount":142},[],{"trials":2394,"activeCount":142},[2395],{"nctId":2396,"briefTitle":2397,"status":114,"phases":2398,"start":2399,"conditions":2400,"interventions":2401},"NCT00002824","Gene Therapy in Treating Patients With Primary Brain Tumors",[88],"1996-02",[2201],[2402,2389,2403],"gene therapy","ganciclovir",{"trials":2405,"activeCount":142},[2406],{"nctId":2407,"briefTitle":2408,"status":279,"phases":2409,"primaryCompletion":2410,"completion":2411,"start":2412,"enrollment":920,"conditions":2413,"interventions":2415},"NCT00601848","Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura",[89],"2012-02","2012-12","2004-11",[21,2414],"Metastatic Cancer",[2389,2416],"porfimer sodium",{"trials":2418,"activeCount":142},[],{"trials":2420,"activeCount":142},[],{"trials":2422,"activeCount":142},[],{"intervention":2424,"totalTrials":500,"cells":2425},"Hydroxychloroquine Pill",{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2440,"PHASE3":2454,"PHASE4":2456,"NA":2458},{"trials":2427,"activeCount":142},[],{"trials":2429,"activeCount":142},[2430],{"nctId":2431,"briefTitle":2432,"status":279,"phases":2433,"primaryCompletion":2434,"completion":2434,"start":2435,"enrollment":252,"conditions":2436,"interventions":2438},"NCT04873895","TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)",[88],"2024-04-25","2022-01-24",[2437],"Colorectal Neoplasms Malignant",[2439,2424],"Axitinib 5 MG",{"trials":2441,"activeCount":142},[2442],{"nctId":2443,"briefTitle":2444,"status":114,"phases":2445,"primaryCompletion":2446,"completion":2447,"start":2448,"enrollment":920,"conditions":2449,"interventions":2452},"NCT04735068","Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer",[89],"2022-08-21","2023-12-31","2021-04-09",[2450,2451],"Non-Small Cell Lung Cancer","KRAS Mutation-Related Tumors",[2453,2424],"Binimetinib Pill",{"trials":2455,"activeCount":142},[],{"trials":2457,"activeCount":142},[],{"trials":2459,"activeCount":142},[],{"intervention":356,"totalTrials":500,"cells":2461},{"EARLY_PHASE1":2462,"PHASE1":2468,"PHASE2":2470,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2463,"activeCount":142},[2464],{"nctId":348,"briefTitle":349,"status":114,"phases":2465,"primaryCompletion":351,"completion":351,"start":352,"enrollment":198,"conditions":2466,"interventions":2467},[87],[354],[42,356],{"trials":2469,"activeCount":142},[],{"trials":2471,"activeCount":142},[2472],{"nctId":2473,"briefTitle":2474,"status":279,"phases":2475,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":2479,"conditions":2480,"interventions":2485},"NCT00776373","Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed\u002FRefractory Aggressive Lymphoid Malignancies",[88,89],"2008-12","2009-12","2007-01",4,[2481,2482,2483,2484],"ALL","Burkitt's Lymphoma","Lymphoblastic Leukemia","CML",[356,2486],"High dose etoposide and cytarabine",{"trials":2488,"activeCount":142},[],{"trials":2490,"activeCount":142},[],{"trials":2492,"activeCount":142},[],{"intervention":2494,"totalTrials":500,"cells":2495},"Maraviroc 300 mg",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2497,"activeCount":142},[],{"trials":2499,"activeCount":142},[],{"trials":2501,"activeCount":142},[2502,2512],{"nctId":2503,"briefTitle":2504,"status":114,"phases":2505,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":1453,"conditions":2509,"interventions":2511},"NCT01785810","Phase II Maraviroc for GVHD Prevention",[89],"2016-11-11","2018-07-12","2013-02",[2510],"Hematologic Malignancy",[2494],{"nctId":2513,"briefTitle":2514,"status":114,"phases":2515,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":400,"conditions":2518,"interventions":2521},"NCT00948753","Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation",[88,89],"2011-04","2009-06",[2519,2520],"Graft-versus-host Disease","Hematopoietic Stem Cell Transplantation",[2522,2494,2523],"Maraviroc 150 MG","Maraviroc 300 mg Phase II",{"trials":2525,"activeCount":142},[],{"trials":2527,"activeCount":142},[],{"trials":2529,"activeCount":142},[],{"intervention":2531,"totalTrials":500,"cells":2532},"Protein expression analysis",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2534,"activeCount":142},[],{"trials":2536,"activeCount":142},[],{"trials":2538,"activeCount":142},[2539,2549],{"nctId":2540,"briefTitle":2541,"status":279,"phases":2542,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":36,"conditions":2545,"interventions":2546},"NCT01253668","Brivanib Metastatic Renal Cell Carcinoma",[89],"2013-09","2011-11",[106],[2547,2548,2531],"Brivanib alaninate","Polymerase chain reaction",{"nctId":1776,"briefTitle":1777,"status":114,"phases":2550,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1781,"conditions":2551,"interventions":2552},[88,89],[21],[1706,1750,1784,1785],{"trials":2554,"activeCount":142},[],{"trials":2556,"activeCount":142},[],{"trials":2558,"activeCount":142},[],{"intervention":1750,"totalTrials":500,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2575,"PHASE4":2577,"NA":2579},{"trials":2562,"activeCount":142},[],{"trials":2564,"activeCount":142},[],{"trials":2566,"activeCount":142},[2567,2571],{"nctId":1741,"briefTitle":1742,"status":114,"phases":2568,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":728,"conditions":2569,"interventions":2570},[88,89],[1748],[1706,1750],{"nctId":1776,"briefTitle":1777,"status":114,"phases":2572,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1781,"conditions":2573,"interventions":2574},[88,89],[21],[1706,1750,1784,1785],{"trials":2576,"activeCount":142},[],{"trials":2578,"activeCount":142},[],{"trials":2580,"activeCount":142},[],{"intervention":705,"totalTrials":9,"cells":2582},{"EARLY_PHASE1":2583,"PHASE1":2585,"PHASE2":2587,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2584,"activeCount":142},[],{"trials":2586,"activeCount":142},[],{"trials":2588,"activeCount":142},[2589],{"nctId":695,"briefTitle":696,"status":279,"phases":2590,"primaryCompletion":698,"completion":699,"start":700,"enrollment":252,"conditions":2591,"interventions":2592},[89],[33],[703,704,705,706],{"trials":2594,"activeCount":142},[],{"trials":2596,"activeCount":142},[],{"trials":2598,"activeCount":142},[],{"intervention":2600,"totalTrials":9,"cells":2601},"OC-L\u002FMontanide ISA 51 VG",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2617,"PHASE4":2619,"NA":2621},{"trials":2603,"activeCount":142},[],{"trials":2605,"activeCount":142},[],{"trials":2607,"activeCount":142},[2608],{"nctId":2609,"briefTitle":2610,"status":279,"phases":2611,"primaryCompletion":363,"completion":2612,"start":2516,"enrollment":336,"conditions":2613,"interventions":2614},"NCT01312389","A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[88,89],"2012-08-17",[27,2103,2104],[2600,2615,2616],"Ampligen","Prevnar",{"trials":2618,"activeCount":142},[],{"trials":2620,"activeCount":142},[],{"trials":2622,"activeCount":142},[],{"intervention":2615,"totalTrials":9,"cells":2624},{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2635,"PHASE4":2637,"NA":2639},{"trials":2626,"activeCount":142},[],{"trials":2628,"activeCount":142},[],{"trials":2630,"activeCount":142},[2631],{"nctId":2609,"briefTitle":2610,"status":279,"phases":2632,"primaryCompletion":363,"completion":2612,"start":2516,"enrollment":336,"conditions":2633,"interventions":2634},[88,89],[27,2103,2104],[2600,2615,2616],{"trials":2636,"activeCount":142},[],{"trials":2638,"activeCount":142},[],{"trials":2640,"activeCount":142},[],{"intervention":2616,"totalTrials":9,"cells":2642},{"EARLY_PHASE1":2643,"PHASE1":2645,"PHASE2":2647,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2644,"activeCount":142},[],{"trials":2646,"activeCount":142},[],{"trials":2648,"activeCount":142},[2649],{"nctId":2609,"briefTitle":2610,"status":279,"phases":2650,"primaryCompletion":363,"completion":2612,"start":2516,"enrollment":336,"conditions":2651,"interventions":2652},[88,89],[27,2103,2104],[2600,2615,2616],{"trials":2654,"activeCount":142},[],{"trials":2656,"activeCount":142},[],{"trials":2658,"activeCount":142},[],{"intervention":2660,"totalTrials":9,"cells":2661},"Bevacizumab 5 mg\u002Fkg",{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2666,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2663,"activeCount":142},[],{"trials":2665,"activeCount":142},[],{"trials":2667,"activeCount":142},[2668],{"nctId":2669,"briefTitle":2670,"status":138,"phases":2671,"primaryCompletion":2672,"completion":2672,"start":1755,"enrollment":142,"conditions":2673,"interventions":2675},"NCT01426074","DCE-MRI PET Bevacizumab Study in Rectal Cancer",[89],"2014-06-11",[2674],"Rectal Cancer Patients",[2660],{"trials":2677,"activeCount":142},[],{"trials":2679,"activeCount":142},[],{"trials":2681,"activeCount":142},[],{"intervention":2683,"totalTrials":9,"cells":2684},"Transarterial chemoembolization",{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2704,"PHASE4":2706,"NA":2708},{"trials":2686,"activeCount":142},[],{"trials":2688,"activeCount":142},[],{"trials":2690,"activeCount":142},[2691],{"nctId":2692,"briefTitle":2693,"status":114,"phases":2694,"primaryCompletion":2695,"completion":2696,"start":2697,"enrollment":2698,"conditions":2699,"interventions":2702},"NCT02724540","Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver",[89],"2024-04-30","2024-11-08","2016-03",162,[2700,2701],"Neuroendocrine Tumor, Malignant","Liver Metastases",[2683,2703],"Drug Eluting Beads Embolization",{"trials":2705,"activeCount":142},[],{"trials":2707,"activeCount":142},[],{"trials":2709,"activeCount":142},[],{"intervention":2703,"totalTrials":9,"cells":2711},{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2713,"activeCount":142},[],{"trials":2715,"activeCount":142},[],{"trials":2717,"activeCount":142},[2718],{"nctId":2692,"briefTitle":2693,"status":114,"phases":2719,"primaryCompletion":2695,"completion":2696,"start":2697,"enrollment":2698,"conditions":2720,"interventions":2721},[89],[2700,2701],[2683,2703],{"trials":2723,"activeCount":142},[],{"trials":2725,"activeCount":142},[],{"trials":2727,"activeCount":142},[],{"intervention":2729,"totalTrials":9,"cells":2730},"brentuximab vedotin",{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2746,"PHASE4":2748,"NA":2750},{"trials":2732,"activeCount":142},[],{"trials":2734,"activeCount":142},[],{"trials":2736,"activeCount":142},[2737],{"nctId":2738,"briefTitle":2739,"status":114,"phases":2740,"primaryCompletion":140,"completion":2100,"start":364,"enrollment":221,"conditions":2741,"interventions":2745},"NCT01994850","Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients",[88,89],[2742,2743,2744],"CD30 Positive Primary Mediastinal Large B-cell Lymphoma","CD30-Positive Diffuse Large B-Cell Lymphoma","CD30-Positive Gray Zone Lymphoma",[2729],{"trials":2747,"activeCount":142},[],{"trials":2749,"activeCount":142},[],{"trials":2751,"activeCount":142},[],{"intervention":2288,"totalTrials":9,"cells":2753},{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2764,"PHASE4":2766,"NA":2768},{"trials":2755,"activeCount":142},[],{"trials":2757,"activeCount":142},[],{"trials":2759,"activeCount":142},[2760],{"nctId":2273,"briefTitle":2274,"status":114,"phases":2761,"primaryCompletion":2276,"completion":2277,"start":2278,"enrollment":424,"conditions":2762,"interventions":2763},[89],[2280,2281,2282,2283,2284,2285,2286],[2255,2288,2289],{"trials":2765,"activeCount":142},[],{"trials":2767,"activeCount":142},[],{"trials":2769,"activeCount":142},[],{"intervention":2289,"totalTrials":9,"cells":2771},{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2773,"activeCount":142},[],{"trials":2775,"activeCount":142},[],{"trials":2777,"activeCount":142},[2778],{"nctId":2273,"briefTitle":2274,"status":114,"phases":2779,"primaryCompletion":2276,"completion":2277,"start":2278,"enrollment":424,"conditions":2780,"interventions":2781},[89],[2280,2281,2282,2283,2284,2285,2286],[2255,2288,2289],{"trials":2783,"activeCount":142},[],{"trials":2785,"activeCount":142},[],{"trials":2787,"activeCount":142},[],{"intervention":2789,"totalTrials":9,"cells":2790},"Birinapant",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2792,"activeCount":142},[],{"trials":2794,"activeCount":142},[],{"trials":2796,"activeCount":142},[2797],{"nctId":2798,"briefTitle":2799,"status":279,"phases":2800,"primaryCompletion":2801,"completion":153,"start":2544,"enrollment":168,"conditions":2802,"interventions":2804},"NCT01486784","A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia",[88,89],"2014-11",[2803],"Acute Myelogenous Leukemia",[2789],{"trials":2806,"activeCount":142},[],{"trials":2808,"activeCount":142},[],{"trials":2810,"activeCount":142},[],{"intervention":2812,"totalTrials":9,"cells":2813},"PD-0332991",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2815,"activeCount":142},[],{"trials":2817,"activeCount":142},[],{"trials":2819,"activeCount":142},[2820],{"nctId":2821,"briefTitle":2822,"status":114,"phases":2823,"primaryCompletion":2824,"completion":2824,"start":699,"enrollment":2825,"conditions":2826,"interventions":2866},"NCT01037790","Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer",[89],"2019-10",304,[2827,2828,2829,2830,2831,2832,2833,2834,2835,2836,2837,2838,2839,2840,2841,2842,2843,2844,2845,2846,2847,2848,2849,2850,2851,2852,2853,2854,2855,2856,2857,2858,2859,2860,2861,2862,2863,2864,2865],"Adult Solid Tumor","Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum","Adult Central Nervous System Germ Cell Tumor","Adult Teratoma","Benign Teratoma","Estrogen Receptor-negative Breast Cancer","Estrogen Receptor-positive Breast Cancer","Familial Testicular Germ Cell Tumor","HER2-negative Breast Cancer","HER2-positive Breast Cancer","Male Breast Cancer","Ovarian Immature Teratoma","Ovarian Mature Teratoma","Ovarian Monodermal and Highly Specialized Teratoma","Progesterone Receptor-negative Breast Cancer","Progesterone Receptor-positive Breast Cancer","Recurrent Breast Cancer","Recurrent Colon Cancer","Recurrent Extragonadal Germ Cell Tumor","Recurrent Extragonadal Non-seminomatous Germ Cell Tumor","Recurrent Extragonadal Seminoma","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Melanoma","Recurrent Ovarian Germ Cell Tumor","Recurrent Rectal Cancer","Stage III Extragonadal Non-seminomatous Germ Cell Tumor","Stage III Extragonadal Seminoma","Stage III Malignant Testicular Germ Cell Tumor","Stage III Ovarian Germ Cell Tumor","Stage IV Breast Cancer","Stage IV Colon Cancer","Stage IV Extragonadal Non-seminomatous Germ Cell Tumor","Stage IV Extragonadal Seminoma","Stage IV Melanoma","Stage IV Ovarian Germ Cell Tumor","Stage IV Rectal Cancer","Testicular Immature Teratoma","Testicular Mature Teratoma",[2812],{"trials":2868,"activeCount":142},[],{"trials":2870,"activeCount":142},[],{"trials":2872,"activeCount":142},[],{"intervention":2874,"totalTrials":9,"cells":2875},"Ruxolitinib",{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2892,"PHASE4":2894,"NA":2896},{"trials":2877,"activeCount":142},[],{"trials":2879,"activeCount":142},[],{"trials":2881,"activeCount":142},[2882],{"nctId":2883,"briefTitle":2884,"status":114,"phases":2885,"primaryCompletion":2886,"completion":2887,"start":2269,"enrollment":378,"conditions":2888,"interventions":2890},"NCT01594216","Ruxolitinib in Estrogen Receptor Positive Breast Cancer",[89],"2016-04","2016-04-09",[2889],"Estrogen-receptor Positive Invasive Metastatic Breast Cancer",[2874,2891],"Exemestane",{"trials":2893,"activeCount":142},[],{"trials":2895,"activeCount":142},[],{"trials":2897,"activeCount":142},[],{"intervention":2891,"totalTrials":9,"cells":2899},{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2904,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2901,"activeCount":142},[],{"trials":2903,"activeCount":142},[],{"trials":2905,"activeCount":142},[2906],{"nctId":2883,"briefTitle":2884,"status":114,"phases":2907,"primaryCompletion":2886,"completion":2887,"start":2269,"enrollment":378,"conditions":2908,"interventions":2909},[89],[2889],[2874,2891],{"trials":2911,"activeCount":142},[],{"trials":2913,"activeCount":142},[],{"trials":2915,"activeCount":142},[],{"intervention":2917,"totalTrials":9,"cells":2918},"Donepezil",{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2920,"activeCount":142},[],{"trials":2922,"activeCount":142},[],{"trials":2924,"activeCount":142},[2925],{"nctId":2926,"briefTitle":2927,"status":114,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":104,"conditions":2931,"interventions":2932},"NCT01250977","Effect of Donepezil on Smoking",[89],"2011-12-06","2011-01-11",[35],[2917],{"trials":2934,"activeCount":142},[],{"trials":2936,"activeCount":142},[],{"trials":2938,"activeCount":142},[],{"intervention":2940,"totalTrials":9,"cells":2941},"HER-2 Pulsed Dendritic cell Vaccine",{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2958,"PHASE4":2960,"NA":2962},{"trials":2943,"activeCount":142},[],{"trials":2945,"activeCount":142},[],{"trials":2947,"activeCount":142},[2948],{"nctId":2949,"briefTitle":2950,"status":114,"phases":2951,"primaryCompletion":2952,"completion":2953,"start":698,"enrollment":2954,"conditions":2955,"interventions":2957},"NCT02061332","DC Vaccine for Patients With Ductal Carcinoma In Situ",[88,89],"2014-08-08","2015-10-07",58,[15,2956],"DCIS",[2940],{"trials":2959,"activeCount":142},[],{"trials":2961,"activeCount":142},[],{"trials":2963,"activeCount":142},[],{"intervention":2965,"totalTrials":9,"cells":2966},"Gemcitabine, Irinotecan, Panitumumab",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2983,"PHASE4":2985,"NA":2987},{"trials":2968,"activeCount":142},[],{"trials":2970,"activeCount":142},[],{"trials":2972,"activeCount":142},[2973],{"nctId":2974,"briefTitle":2975,"status":114,"phases":2976,"primaryCompletion":2977,"completion":2978,"start":2199,"enrollment":1374,"conditions":2979,"interventions":2982},"NCT00948935","Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma",[89],"2014-09","2014-09-26",[2980,2981],"Biliary Cancer","Cholangiocarcinoma",[2965],{"trials":2984,"activeCount":142},[],{"trials":2986,"activeCount":142},[],{"trials":2988,"activeCount":142},[],{"intervention":2990,"totalTrials":9,"cells":2991},"Armodafinil",{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":3007,"PHASE4":3009,"NA":3011},{"trials":2993,"activeCount":142},[],{"trials":2995,"activeCount":142},[],{"trials":2997,"activeCount":142},[2998],{"nctId":2999,"briefTitle":3000,"status":114,"phases":3001,"primaryCompletion":3002,"completion":3003,"start":2517,"enrollment":3004,"conditions":3005,"interventions":3006},"NCT01019187","Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy",[89],"2013-08","2015-08",226,[368],[2990,2990],{"trials":3008,"activeCount":142},[],{"trials":3010,"activeCount":142},[],{"trials":3012,"activeCount":142},[],{"intervention":453,"totalTrials":9,"cells":3014},{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3025,"PHASE4":3027,"NA":3029},{"trials":3016,"activeCount":142},[],{"trials":3018,"activeCount":142},[],{"trials":3020,"activeCount":142},[3021],{"nctId":445,"briefTitle":446,"status":138,"phases":3022,"primaryCompletion":448,"completion":449,"start":450,"enrollment":142,"conditions":3023,"interventions":3024},[88,89],[15],[42,453],{"trials":3026,"activeCount":142},[],{"trials":3028,"activeCount":142},[],{"trials":3030,"activeCount":142},[],{"intervention":463,"totalTrials":9,"cells":3032},{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3043,"PHASE4":3045,"NA":3047},{"trials":3034,"activeCount":142},[],{"trials":3036,"activeCount":142},[],{"trials":3038,"activeCount":142},[3039],{"nctId":455,"briefTitle":456,"status":114,"phases":3040,"primaryCompletion":458,"completion":458,"start":459,"enrollment":424,"conditions":3041,"interventions":3042},[88,89],[461],[463,370,464],{"trials":3044,"activeCount":142},[],{"trials":3046,"activeCount":142},[],{"trials":3048,"activeCount":142},[],{"intervention":464,"totalTrials":9,"cells":3050},{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3061,"PHASE4":3063,"NA":3065},{"trials":3052,"activeCount":142},[],{"trials":3054,"activeCount":142},[],{"trials":3056,"activeCount":142},[3057],{"nctId":455,"briefTitle":456,"status":114,"phases":3058,"primaryCompletion":458,"completion":458,"start":459,"enrollment":424,"conditions":3059,"interventions":3060},[88,89],[461],[463,370,464],{"trials":3062,"activeCount":142},[],{"trials":3064,"activeCount":142},[],{"trials":3066,"activeCount":142},[],{"intervention":3068,"totalTrials":9,"cells":3069},"Capecitabine, Oxaliplatin and Cetuximab",{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3071,"activeCount":142},[],{"trials":3073,"activeCount":142},[],{"trials":3075,"activeCount":142},[3076],{"nctId":3077,"briefTitle":3078,"status":279,"phases":3079,"primaryCompletion":352,"completion":352,"start":700,"enrollment":198,"conditions":3080,"interventions":3081},"NCT00353457","Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma",[89],[426],[3068],{"trials":3083,"activeCount":142},[],{"trials":3085,"activeCount":142},[],{"trials":3087,"activeCount":142},[],{"intervention":1446,"totalTrials":9,"cells":3089},{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3094,"PHASE3":3100,"PHASE4":3102,"NA":3104},{"trials":3091,"activeCount":142},[],{"trials":3093,"activeCount":142},[],{"trials":3095,"activeCount":142},[3096],{"nctId":1437,"briefTitle":1438,"status":114,"phases":3097,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":221,"conditions":3098,"interventions":3099},[89],[1444],[498,499,1446],{"trials":3101,"activeCount":142},[],{"trials":3103,"activeCount":142},[],{"trials":3105,"activeCount":142},[],{"intervention":3107,"totalTrials":9,"cells":3108},"GC1008",{"EARLY_PHASE1":3109,"PHASE1":3111,"PHASE2":3113,"PHASE3":3124,"PHASE4":3126,"NA":3128},{"trials":3110,"activeCount":142},[],{"trials":3112,"activeCount":142},[],{"trials":3114,"activeCount":142},[3115],{"nctId":3116,"briefTitle":3117,"status":114,"phases":3118,"primaryCompletion":351,"completion":3119,"start":3120,"enrollment":1556,"conditions":3121,"interventions":3123},"NCT01112293","Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma",[89],"2014-12","2010-04",[3122],"Pleural Malignant Mesothelioma",[3107],{"trials":3125,"activeCount":142},[],{"trials":3127,"activeCount":142},[],{"trials":3129,"activeCount":142},[],{"intervention":3131,"totalTrials":9,"cells":3132},"Gleevec",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3149,"PHASE4":3151,"NA":3153},{"trials":3134,"activeCount":142},[],{"trials":3136,"activeCount":142},[],{"trials":3138,"activeCount":142},[3139],{"nctId":3140,"briefTitle":3141,"status":279,"phases":3142,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":221,"conditions":3145,"interventions":3147},"NCT00667953","Study of Temzolomide and Gleevec in Advanced Melanoma",[88,89],"2011-03-09","2003-01",[231,3146],"Advanced Melanoma",[3131,3148],"Temodar",{"trials":3150,"activeCount":142},[],{"trials":3152,"activeCount":142},[],{"trials":3154,"activeCount":142},[],{"intervention":3148,"totalTrials":9,"cells":3156},{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3167,"PHASE4":3169,"NA":3171},{"trials":3158,"activeCount":142},[],{"trials":3160,"activeCount":142},[],{"trials":3162,"activeCount":142},[3163],{"nctId":3140,"briefTitle":3141,"status":279,"phases":3164,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":221,"conditions":3165,"interventions":3166},[88,89],[231,3146],[3131,3148],{"trials":3168,"activeCount":142},[],{"trials":3170,"activeCount":142},[],{"trials":3172,"activeCount":142},[],{"intervention":3174,"totalTrials":9,"cells":3175},"CTL019",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3177,"activeCount":142},[],{"trials":3179,"activeCount":142},[],{"trials":3181,"activeCount":142},[3182],{"nctId":3183,"briefTitle":3184,"status":138,"phases":3185,"primaryCompletion":3186,"start":264,"enrollment":142,"conditions":3187,"interventions":3191},"NCT02167360","Study of Efficacy and Safety of CTL019 in Adult ALL Patients",[89],"2017-01-11",[3188,3189,3190],"B-cell Acute Lymphoblastic Leukemia","Relapsed B-cell Acute Lymphoblastic Leukemia","Refractory B-cell Acute Lymphoblastic Leukemia",[3174],{"trials":3193,"activeCount":142},[],{"trials":3195,"activeCount":142},[],{"trials":3197,"activeCount":142},[],{"intervention":2453,"totalTrials":9,"cells":3199},{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3201,"activeCount":142},[],{"trials":3203,"activeCount":142},[],{"trials":3205,"activeCount":142},[3206],{"nctId":2443,"briefTitle":2444,"status":114,"phases":3207,"primaryCompletion":2446,"completion":2447,"start":2448,"enrollment":920,"conditions":3208,"interventions":3209},[89],[2450,2451],[2453,2424],{"trials":3211,"activeCount":142},[],{"trials":3213,"activeCount":142},[],{"trials":3215,"activeCount":142},[],{"intervention":3217,"totalTrials":9,"cells":3218},"Dovitinib",{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3238,"PHASE4":3240,"NA":3242},{"trials":3220,"activeCount":142},[],{"trials":3222,"activeCount":142},[],{"trials":3224,"activeCount":142},[3225],{"nctId":3226,"briefTitle":3227,"status":114,"phases":3228,"primaryCompletion":2697,"completion":3229,"start":2083,"enrollment":412,"conditions":3230,"interventions":3237},"NCT01635907","Dovitinib in Neuroendocrine Tumors",[89],"2016-04-11",[3231,3232,3233,3234,3235,3236],"Advanced Metastatic Paraganglioma","Advanced Metastatic Pheochromocytoma","Recurrent Paraganglioma","Recurrent Pheochromocytoma","Unresectable Paraganglioma","Unresectable Pheochromocytoma",[3217],{"trials":3239,"activeCount":142},[],{"trials":3241,"activeCount":142},[],{"trials":3243,"activeCount":142},[],{"intervention":981,"totalTrials":9,"cells":3245},{"EARLY_PHASE1":3246,"PHASE1":3248,"PHASE2":3250,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3247,"activeCount":142},[],{"trials":3249,"activeCount":142},[],{"trials":3251,"activeCount":142},[3252],{"nctId":973,"briefTitle":974,"status":114,"phases":3253,"primaryCompletion":976,"completion":976,"start":977,"enrollment":366,"conditions":3254,"interventions":3255},[89],[979],[981,964,982,983],{"trials":3257,"activeCount":142},[],{"trials":3259,"activeCount":142},[],{"trials":3261,"activeCount":142},[],{"intervention":982,"totalTrials":9,"cells":3263},{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3268,"PHASE3":3274,"PHASE4":3276,"NA":3278},{"trials":3265,"activeCount":142},[],{"trials":3267,"activeCount":142},[],{"trials":3269,"activeCount":142},[3270],{"nctId":973,"briefTitle":974,"status":114,"phases":3271,"primaryCompletion":976,"completion":976,"start":977,"enrollment":366,"conditions":3272,"interventions":3273},[89],[979],[981,964,982,983],{"trials":3275,"activeCount":142},[],{"trials":3277,"activeCount":142},[],{"trials":3279,"activeCount":142},[],{"intervention":983,"totalTrials":9,"cells":3281},{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3292,"PHASE4":3294,"NA":3296},{"trials":3283,"activeCount":142},[],{"trials":3285,"activeCount":142},[],{"trials":3287,"activeCount":142},[3288],{"nctId":973,"briefTitle":974,"status":114,"phases":3289,"primaryCompletion":976,"completion":976,"start":977,"enrollment":366,"conditions":3290,"interventions":3291},[89],[979],[981,964,982,983],{"trials":3293,"activeCount":142},[],{"trials":3295,"activeCount":142},[],{"trials":3297,"activeCount":142},[],{"intervention":3299,"totalTrials":9,"cells":3300},"lapatinib ditosylate",{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3335,"PHASE4":3337,"NA":3339},{"trials":3302,"activeCount":142},[],{"trials":3304,"activeCount":142},[],{"trials":3306,"activeCount":142},[3307],{"nctId":3308,"briefTitle":3309,"status":114,"phases":3310,"primaryCompletion":3311,"completion":3312,"start":699,"enrollment":472,"conditions":3313,"interventions":3333},"NCT01044433","Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck",[89],"2015-09-24","2017-03-03",[30,3314,3315,3316,3317,3318,3319,3320,3321,3322,3323,3324,3325,3326,3327,3328,3329,3330,3331,3332],"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity",[3299,3334],"capecitabine",{"trials":3336,"activeCount":142},[],{"trials":3338,"activeCount":142},[],{"trials":3340,"activeCount":142},[],{"intervention":3334,"totalTrials":9,"cells":3342},{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3353,"PHASE4":3355,"NA":3357},{"trials":3344,"activeCount":142},[],{"trials":3346,"activeCount":142},[],{"trials":3348,"activeCount":142},[3349],{"nctId":3308,"briefTitle":3309,"status":114,"phases":3350,"primaryCompletion":3311,"completion":3312,"start":699,"enrollment":472,"conditions":3351,"interventions":3352},[89],[30,3314,3315,3316,3317,3318,3319,3320,3321,3322,3323,3324,3325,3326,3327,3328,3329,3330,3331,3332],[3299,3334],{"trials":3354,"activeCount":142},[],{"trials":3356,"activeCount":142},[],{"trials":3358,"activeCount":142},[],{"intervention":3360,"totalTrials":9,"cells":3361},"Eltrombopag",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3378,"PHASE4":3380,"NA":3382},{"trials":3363,"activeCount":142},[],{"trials":3365,"activeCount":142},[],{"trials":3367,"activeCount":142},[3368],{"nctId":3369,"briefTitle":3370,"status":279,"phases":3371,"primaryCompletion":3372,"completion":3373,"start":3374,"enrollment":472,"conditions":3375,"interventions":3377},"NCT01113502","Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)",[88,89],"2013-03-14","2015-11-10","2010-06",[3376],"Acute Myelogenous Leukemia (AML)",[3360],{"trials":3379,"activeCount":142},[],{"trials":3381,"activeCount":142},[],{"trials":3383,"activeCount":142},[],{"intervention":719,"totalTrials":9,"cells":3385},{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3396,"PHASE4":3398,"NA":3400},{"trials":3387,"activeCount":142},[],{"trials":3389,"activeCount":142},[],{"trials":3391,"activeCount":142},[3392],{"nctId":712,"briefTitle":713,"status":114,"phases":3393,"primaryCompletion":482,"completion":482,"start":715,"enrollment":716,"conditions":3394,"interventions":3395},[89],[519],[703,704,719,706],{"trials":3397,"activeCount":142},[],{"trials":3399,"activeCount":142},[],{"trials":3401,"activeCount":142},[],{"intervention":2547,"totalTrials":9,"cells":3403},{"EARLY_PHASE1":3404,"PHASE1":3406,"PHASE2":3408,"PHASE3":3414,"PHASE4":3416,"NA":3418},{"trials":3405,"activeCount":142},[],{"trials":3407,"activeCount":142},[],{"trials":3409,"activeCount":142},[3410],{"nctId":2540,"briefTitle":2541,"status":279,"phases":3411,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":36,"conditions":3412,"interventions":3413},[89],[106],[2547,2548,2531],{"trials":3415,"activeCount":142},[],{"trials":3417,"activeCount":142},[],{"trials":3419,"activeCount":142},[],{"intervention":2548,"totalTrials":9,"cells":3421},{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3432,"PHASE4":3434,"NA":3436},{"trials":3423,"activeCount":142},[],{"trials":3425,"activeCount":142},[],{"trials":3427,"activeCount":142},[3428],{"nctId":2540,"briefTitle":2541,"status":279,"phases":3429,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":36,"conditions":3430,"interventions":3431},[89],[106],[2547,2548,2531],{"trials":3433,"activeCount":142},[],{"trials":3435,"activeCount":142},[],{"trials":3437,"activeCount":142},[],{"intervention":3439,"totalTrials":9,"cells":3440},"Topical resiquimod 0.06%",{"EARLY_PHASE1":3441,"PHASE1":3443,"PHASE2":3445,"PHASE3":3457,"PHASE4":3459,"NA":3461},{"trials":3442,"activeCount":142},[],{"trials":3444,"activeCount":142},[],{"trials":3446,"activeCount":142},[3447],{"nctId":3448,"briefTitle":3449,"status":114,"phases":3450,"primaryCompletion":3451,"completion":3452,"start":2410,"enrollment":28,"conditions":3453,"interventions":3455},"NCT01676831","Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)",[88,89],"2015-01","2015-09-28",[3454],"Cutaneous T Cell Lymphoma",[3439,3456],"topical resiquimod 0.03%",{"trials":3458,"activeCount":142},[],{"trials":3460,"activeCount":142},[],{"trials":3462,"activeCount":142},[],{"intervention":3456,"totalTrials":9,"cells":3464},{"EARLY_PHASE1":3465,"PHASE1":3467,"PHASE2":3469,"PHASE3":3475,"PHASE4":3477,"NA":3479},{"trials":3466,"activeCount":142},[],{"trials":3468,"activeCount":142},[],{"trials":3470,"activeCount":142},[3471],{"nctId":3448,"briefTitle":3449,"status":114,"phases":3472,"primaryCompletion":3451,"completion":3452,"start":2410,"enrollment":28,"conditions":3473,"interventions":3474},[88,89],[3454],[3439,3456],{"trials":3476,"activeCount":142},[],{"trials":3478,"activeCount":142},[],{"trials":3480,"activeCount":142},[],{"intervention":3482,"totalTrials":9,"cells":3483},"Niraparib Pill",{"EARLY_PHASE1":3484,"PHASE1":3486,"PHASE2":3488,"PHASE3":3498,"PHASE4":3500,"NA":3502},{"trials":3485,"activeCount":142},[],{"trials":3487,"activeCount":142},[],{"trials":3489,"activeCount":142},[3490],{"nctId":3491,"briefTitle":3492,"status":114,"phases":3493,"primaryCompletion":3494,"completion":3494,"start":3495,"enrollment":31,"conditions":3496,"interventions":3497},"NCT04288687","A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects",[89],"2024-02-20","2020-10-19",[2015],[3482],{"trials":3499,"activeCount":142},[],{"trials":3501,"activeCount":142},[],{"trials":3503,"activeCount":142},[],{"intervention":3505,"totalTrials":9,"cells":3506},"Etirinotecan pegol",{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3508,"activeCount":142},[],{"trials":3510,"activeCount":142},[],{"trials":3512,"activeCount":142},[3513],{"nctId":3514,"briefTitle":3515,"status":114,"phases":3516,"primaryCompletion":208,"completion":3517,"start":3518,"enrollment":366,"conditions":3519,"interventions":3522},"NCT01773109","Etirinotecan Pegol (NKTR-102) in NSCLC",[89],"2017-03-15","2013-01",[3520,3521],"Metastatic Non Small Cell Lung Cancer","Recurrent Non Small Cell Lung Cancer",[3505],{"trials":3524,"activeCount":142},[],{"trials":3526,"activeCount":142},[],{"trials":3528,"activeCount":142},[],{"intervention":1774,"totalTrials":9,"cells":3530},{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3532,"activeCount":142},[],{"trials":3534,"activeCount":142},[],{"trials":3536,"activeCount":142},[3537],{"nctId":1766,"briefTitle":1767,"status":279,"phases":3538,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1374,"conditions":3539,"interventions":3540},[89],[30],[1774,1706,704],{"trials":3542,"activeCount":142},[],{"trials":3544,"activeCount":142},[],{"trials":3546,"activeCount":142},[],{"intervention":3548,"totalTrials":9,"cells":3549},"Nelfinavir (Viracept®) 1250 mg",{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3554,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3551,"activeCount":142},[],{"trials":3553,"activeCount":142},[],{"trials":3555,"activeCount":142},[3556],{"nctId":3557,"briefTitle":3558,"status":114,"phases":3559,"primaryCompletion":3560,"completion":3561,"start":1428,"enrollment":22,"conditions":3562,"interventions":3564},"NCT02207439","Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck",[89],"2021-05","2022-05",[3563],"Head and Neck Squamous Cell Carcinoma",[3548],{"trials":3566,"activeCount":142},[],{"trials":3568,"activeCount":142},[],{"trials":3570,"activeCount":142},[],{"intervention":2416,"totalTrials":9,"cells":3572},{"EARLY_PHASE1":3573,"PHASE1":3575,"PHASE2":3577,"PHASE3":3583,"PHASE4":3585,"NA":3587},{"trials":3574,"activeCount":142},[],{"trials":3576,"activeCount":142},[],{"trials":3578,"activeCount":142},[3579],{"nctId":2407,"briefTitle":2408,"status":279,"phases":3580,"primaryCompletion":2410,"completion":2411,"start":2412,"enrollment":920,"conditions":3581,"interventions":3582},[89],[21,2414],[2389,2416],{"trials":3584,"activeCount":142},[],{"trials":3586,"activeCount":142},[],{"trials":3588,"activeCount":142},[],{"intervention":3590,"totalTrials":9,"cells":3591},"Gabapentin",{"EARLY_PHASE1":3592,"PHASE1":3594,"PHASE2":3596,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3593,"activeCount":142},[],{"trials":3595,"activeCount":142},[],{"trials":3597,"activeCount":142},[3598],{"nctId":3599,"briefTitle":3600,"status":114,"phases":3601,"primaryCompletion":3602,"completion":3602,"start":3603,"enrollment":3604,"conditions":3605,"interventions":3607},"NCT01005108","Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors",[89],"2014-01-31","2009-01",120,[3606],"Hot Flashes",[3590],{"trials":3609,"activeCount":142},[],{"trials":3611,"activeCount":142},[],{"trials":3613,"activeCount":142},[],{"intervention":3615,"totalTrials":9,"cells":3616},"comparative genomic hybridization",{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3618,"activeCount":142},[],{"trials":3620,"activeCount":142},[],{"trials":3622,"activeCount":142},[3623],{"nctId":3624,"briefTitle":3625,"status":3626,"phases":3627,"primaryCompletion":3628,"start":399,"enrollment":129,"conditions":3629,"interventions":3631},"NCT00717587","Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer","UNKNOWN",[89],"2010-07",[3630],"Kidney Cancer",[3632,3633,3615,3634,3635,3636],"motexafin gadolinium","sunitinib malate","gene expression analysis","mutation analysis","polymorphism analysis",{"trials":3638,"activeCount":142},[],{"trials":3640,"activeCount":142},[],{"trials":3642,"activeCount":142},[],{"intervention":3634,"totalTrials":9,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3646,"activeCount":142},[],{"trials":3648,"activeCount":142},[],{"trials":3650,"activeCount":142},[3651],{"nctId":3624,"briefTitle":3625,"status":3626,"phases":3652,"primaryCompletion":3628,"start":399,"enrollment":129,"conditions":3653,"interventions":3654},[89],[3630],[3632,3633,3615,3634,3635,3636],{"trials":3656,"activeCount":142},[],{"trials":3658,"activeCount":142},[],{"trials":3660,"activeCount":142},[],{"intervention":3636,"totalTrials":9,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3673,"PHASE4":3675,"NA":3677},{"trials":3664,"activeCount":142},[],{"trials":3666,"activeCount":142},[],{"trials":3668,"activeCount":142},[3669],{"nctId":3624,"briefTitle":3625,"status":3626,"phases":3670,"primaryCompletion":3628,"start":399,"enrollment":129,"conditions":3671,"interventions":3672},[89],[3630],[3632,3633,3615,3634,3635,3636],{"trials":3674,"activeCount":142},[],{"trials":3676,"activeCount":142},[],{"trials":3678,"activeCount":142},[],{"intervention":3680,"totalTrials":9,"cells":3681},"Sorafenib + Docetaxel\u002FCarboplatin",{"EARLY_PHASE1":3682,"PHASE1":3684,"PHASE2":3686,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3683,"activeCount":142},[],{"trials":3685,"activeCount":142},[],{"trials":3687,"activeCount":142},[3688],{"nctId":3689,"briefTitle":3690,"status":114,"phases":3691,"primaryCompletion":1755,"completion":2411,"start":3692,"enrollment":508,"conditions":3693,"interventions":3694},"NCT00647426","Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB\u002FIV NSCLC",[89],"2007-11",[2450],[3680],{"trials":3696,"activeCount":142},[],{"trials":3698,"activeCount":142},[],{"trials":3700,"activeCount":142},[],{"intervention":2486,"totalTrials":9,"cells":3702},{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3707,"PHASE3":3713,"PHASE4":3715,"NA":3717},{"trials":3704,"activeCount":142},[],{"trials":3706,"activeCount":142},[],{"trials":3708,"activeCount":142},[3709],{"nctId":2473,"briefTitle":2474,"status":279,"phases":3710,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":2479,"conditions":3711,"interventions":3712},[88,89],[2481,2482,2483,2484],[356,2486],{"trials":3714,"activeCount":142},[],{"trials":3716,"activeCount":142},[],{"trials":3718,"activeCount":142},[],{"intervention":1467,"totalTrials":9,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3731,"PHASE4":3733,"NA":3735},{"trials":3722,"activeCount":142},[],{"trials":3724,"activeCount":142},[],{"trials":3726,"activeCount":142},[3727],{"nctId":1458,"briefTitle":1459,"status":138,"phases":3728,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":142,"conditions":3729,"interventions":3730},[89],[1465],[1467,499,498],{"trials":3732,"activeCount":142},[],{"trials":3734,"activeCount":142},[],{"trials":3736,"activeCount":142},[],{"intervention":486,"totalTrials":9,"cells":3738},{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3743,"PHASE3":3749,"PHASE4":3751,"NA":3753},{"trials":3740,"activeCount":142},[],{"trials":3742,"activeCount":142},[],{"trials":3744,"activeCount":142},[3745],{"nctId":477,"briefTitle":478,"status":114,"phases":3746,"primaryCompletion":480,"completion":481,"start":482,"enrollment":366,"conditions":3747,"interventions":3748},[88,89],[484],[42,486],{"trials":3750,"activeCount":142},[],{"trials":3752,"activeCount":142},[],{"trials":3754,"activeCount":142},[],{"intervention":2522,"totalTrials":9,"cells":3756},{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3767,"PHASE4":3769,"NA":3771},{"trials":3758,"activeCount":142},[],{"trials":3760,"activeCount":142},[],{"trials":3762,"activeCount":142},[3763],{"nctId":2513,"briefTitle":2514,"status":114,"phases":3764,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":400,"conditions":3765,"interventions":3766},[88,89],[2519,2520],[2522,2494,2523],{"trials":3768,"activeCount":142},[],{"trials":3770,"activeCount":142},[],{"trials":3772,"activeCount":142},[],{"intervention":2523,"totalTrials":9,"cells":3774},{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3776,"activeCount":142},[],{"trials":3778,"activeCount":142},[],{"trials":3780,"activeCount":142},[3781],{"nctId":2513,"briefTitle":2514,"status":114,"phases":3782,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":400,"conditions":3783,"interventions":3784},[88,89],[2519,2520],[2522,2494,2523],{"trials":3786,"activeCount":142},[],{"trials":3788,"activeCount":142},[],{"trials":3790,"activeCount":142},[],{"intervention":3792,"totalTrials":9,"cells":3793},"Bevacizumab, Abraxane",{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3798,"PHASE3":3807,"PHASE4":3809,"NA":3811},{"trials":3795,"activeCount":142},[],{"trials":3797,"activeCount":142},[],{"trials":3799,"activeCount":142},[3800],{"nctId":3801,"briefTitle":3802,"status":114,"phases":3803,"primaryCompletion":2516,"completion":2516,"start":3804,"enrollment":252,"conditions":3805,"interventions":3806},"NCT00472693","Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer",[89],"2007-05",[15],[3792],{"trials":3808,"activeCount":142},[],{"trials":3810,"activeCount":142},[],{"trials":3812,"activeCount":142},[],{"intervention":3814,"totalTrials":9,"cells":3815},"RUCAPARIB",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3832,"PHASE4":3834,"NA":3836},{"trials":3817,"activeCount":142},[],{"trials":3819,"activeCount":142},[],{"trials":3821,"activeCount":142},[3822],{"nctId":3823,"briefTitle":3824,"status":279,"phases":3825,"primaryCompletion":3826,"completion":3827,"start":3828,"enrollment":3829,"conditions":3830,"interventions":3831},"NCT03140670","Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy",[89],"2020-10-29","2023-08-07","2017-09-05",46,[519],[3814],{"trials":3833,"activeCount":142},[],{"trials":3835,"activeCount":142},[],{"trials":3837,"activeCount":142},[],{"intervention":522,"totalTrials":336,"cells":3839},{"EARLY_PHASE1":3840,"PHASE1":3846,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3841,"activeCount":142},[3842],{"nctId":513,"briefTitle":514,"status":279,"phases":3843,"primaryCompletion":516,"completion":516,"start":517,"enrollment":336,"conditions":3844,"interventions":3845},[87],[519],[85,521,498,522],{"trials":3847,"activeCount":142},[3848,3852],{"nctId":1416,"briefTitle":1417,"status":114,"phases":3849,"primaryCompletion":1419,"completion":1419,"start":1420,"enrollment":95,"conditions":3850,"interventions":3851},[88],[1422],[522,499,498],{"nctId":3853,"briefTitle":3854,"status":279,"phases":3855,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":336,"conditions":3859,"interventions":3860},"NCT03300921","A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer",[88],"2020-08-30","2022-03-23","2017-09-28",[519],[522],{"trials":3862,"activeCount":142},[],{"trials":3864,"activeCount":142},[],{"trials":3866,"activeCount":142},[],{"trials":3868,"activeCount":142},[],{"intervention":3870,"totalTrials":336,"cells":3871},"CP-870,893",{"EARLY_PHASE1":3872,"PHASE1":3883,"PHASE2":3899,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3873,"activeCount":142},[3874],{"nctId":3875,"briefTitle":3876,"status":114,"phases":3877,"primaryCompletion":3878,"completion":3878,"start":3879,"enrollment":36,"conditions":3880,"interventions":3882},"NCT02157831","Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors",[87],"2008-02","2005-07",[3881],"Solid Tumors",[3870],{"trials":3884,"activeCount":142},[3885,3892],{"nctId":3886,"briefTitle":3887,"status":114,"phases":3888,"primaryCompletion":1442,"completion":1442,"start":2269,"enrollment":36,"conditions":3889,"interventions":3891},"NCT01456585","Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma",[88],[3890],"Adenocarcinoma Pancreas",[3870],{"nctId":3893,"briefTitle":3894,"status":114,"phases":3895,"primaryCompletion":700,"completion":700,"start":2365,"conditions":3896,"interventions":3898},"NCT02225002","Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors",[88],[3897],"Advanced Solid Tumors",[3870],{"trials":3900,"activeCount":142},[],{"trials":3902,"activeCount":142},[],{"trials":3904,"activeCount":142},[],{"trials":3906,"activeCount":142},[],{"intervention":3908,"totalTrials":500,"cells":3909},"tremelimumab",{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3936,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3911,"activeCount":142},[],{"trials":3913,"activeCount":142},[3914,3924],{"nctId":3915,"briefTitle":3916,"status":114,"phases":3917,"primaryCompletion":3918,"completion":3919,"start":3920,"enrollment":378,"conditions":3921,"interventions":3922},"NCT01103635","Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma",[88],"2016-05","2016-05-02","2010-02",[2850,2861],[3923,3908],"CD40 agonist monoclonal antibody CP-870,893",{"nctId":3925,"briefTitle":3926,"status":114,"phases":3927,"primaryCompletion":3928,"completion":3928,"start":3929,"enrollment":439,"conditions":3930,"interventions":3933},"NCT02639026","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",[88],"2023-06-27","2016-01-26",[3931,231,3932,15,519],"Metastatic","Non Small Cell Lung Cancer (NSCLC)",[3934,3935],"MEDI4736","Tremelimumab",{"trials":3937,"activeCount":142},[],{"trials":3939,"activeCount":142},[],{"trials":3941,"activeCount":142},[],{"trials":3943,"activeCount":142},[],{"intervention":593,"totalTrials":500,"cells":3945},{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3960,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3947,"activeCount":142},[],{"trials":3949,"activeCount":142},[3950,3956],{"nctId":3951,"briefTitle":3952,"status":114,"phases":3953,"primaryCompletion":117,"completion":117,"start":2365,"enrollment":22,"conditions":3954,"interventions":3955},"NCT00077519","Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer",[88],[519],[593],{"nctId":585,"briefTitle":586,"status":114,"phases":3957,"start":588,"enrollment":209,"conditions":3958,"interventions":3959},[88],[21],[591,592,593],{"trials":3961,"activeCount":142},[],{"trials":3963,"activeCount":142},[],{"trials":3965,"activeCount":142},[],{"trials":3967,"activeCount":142},[],{"intervention":3969,"totalTrials":500,"cells":3970},"SCH 721015",{"EARLY_PHASE1":3971,"PHASE1":3973,"PHASE2":3994,"PHASE3":3996,"PHASE4":3998,"NA":4000},{"trials":3972,"activeCount":142},[],{"trials":3974,"activeCount":142},[3975,3984],{"nctId":3976,"briefTitle":3977,"status":114,"phases":3978,"primaryCompletion":3979,"completion":3979,"start":3980,"enrollment":28,"conditions":3981,"interventions":3983},"NCT01212367","Intrapleural Gene Transfer for Pleural Mesothelioma",[88],"2015-05","2009-02",[3982],"Malignant Pleural Mesothelioma",[3969,3969],{"nctId":3985,"briefTitle":3986,"status":114,"phases":3987,"primaryCompletion":3988,"completion":3989,"start":3990,"enrollment":366,"conditions":3991,"interventions":3993},"NCT01119664","Combination Gene Transfer and Chemotherapy",[88],"2013-10-14","2017-03-17","2010-04-27",[3992],"Mesothelioma",[3969],{"trials":3995,"activeCount":142},[],{"trials":3997,"activeCount":142},[],{"trials":3999,"activeCount":142},[],{"trials":4001,"activeCount":142},[],{"intervention":521,"totalTrials":500,"cells":4003},{"EARLY_PHASE1":4004,"PHASE1":4010,"PHASE2":4016,"PHASE3":4018,"PHASE4":4020,"NA":4022},{"trials":4005,"activeCount":142},[4006],{"nctId":513,"briefTitle":514,"status":279,"phases":4007,"primaryCompletion":516,"completion":516,"start":517,"enrollment":336,"conditions":4008,"interventions":4009},[87],[519],[85,521,498,522],{"trials":4011,"activeCount":142},[4012],{"nctId":2038,"briefTitle":2039,"status":114,"phases":4013,"primaryCompletion":897,"completion":897,"start":2041,"enrollment":716,"conditions":4014,"interventions":4015},[88],[519],[2044,2045,2046],{"trials":4017,"activeCount":142},[],{"trials":4019,"activeCount":142},[],{"trials":4021,"activeCount":142},[],{"trials":4023,"activeCount":142},[],{"intervention":4025,"totalTrials":500,"cells":4026},"Bortezomib",{"EARLY_PHASE1":4027,"PHASE1":4038,"PHASE2":4044,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4028,"activeCount":142},[4029],{"nctId":4030,"briefTitle":4031,"status":114,"phases":4032,"primaryCompletion":4033,"completion":4033,"start":4034,"enrollment":31,"conditions":4035,"interventions":4037},"NCT01594242","Autophagy Induction After Bortezomib for Myeloma",[87],"2015-03-02","2012-07-10",[4036],"Multiple Myeloma",[4025],{"trials":4039,"activeCount":142},[4040],{"nctId":373,"briefTitle":374,"status":114,"phases":4041,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":4042,"interventions":4043},[88],[380],[382,370],{"trials":4045,"activeCount":142},[],{"trials":4047,"activeCount":142},[],{"trials":4049,"activeCount":142},[],{"trials":4051,"activeCount":142},[],{"intervention":391,"totalTrials":500,"cells":4053},{"EARLY_PHASE1":4054,"PHASE1":4056,"PHASE2":4074,"PHASE3":4076,"PHASE4":4078,"NA":4080},{"trials":4055,"activeCount":142},[],{"trials":4057,"activeCount":142},[4058,4062],{"nctId":384,"briefTitle":385,"status":114,"phases":4059,"primaryCompletion":387,"completion":387,"start":388,"enrollment":129,"conditions":4060,"interventions":4061},[88],[33],[370,391,392],{"nctId":4063,"briefTitle":4064,"status":138,"phases":4065,"primaryCompletion":4066,"completion":4067,"start":4068,"enrollment":142,"conditions":4069,"interventions":4071},"NCT03760614","A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma",[88],"2022-07","2022-11","2021-01",[4070],"Pancreas Cancer",[4072,4073],"Entinostat","FOLFOX regimen",{"trials":4075,"activeCount":142},[],{"trials":4077,"activeCount":142},[],{"trials":4079,"activeCount":142},[],{"trials":4081,"activeCount":142},[],{"intervention":4083,"totalTrials":9,"cells":4084},"aminolevulinic acid hydrochloride",{"EARLY_PHASE1":4085,"PHASE1":4087,"PHASE2":4097,"PHASE3":4099,"PHASE4":4101,"NA":4103},{"trials":4086,"activeCount":142},[],{"trials":4088,"activeCount":142},[4089],{"nctId":4090,"briefTitle":4091,"status":114,"phases":4092,"primaryCompletion":4093,"completion":4093,"start":3603,"enrollment":1374,"conditions":4094,"interventions":4096},"NCT00978081","Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors",[88],"2016-11",[30,4095],"Precancerous Condition",[4083],{"trials":4098,"activeCount":142},[],{"trials":4100,"activeCount":142},[],{"trials":4102,"activeCount":142},[],{"trials":4104,"activeCount":142},[],{"intervention":4106,"totalTrials":9,"cells":4107},"Galunisertib 150mg by mouth twice a day",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4121,"PHASE3":4123,"PHASE4":4125,"NA":4127},{"trials":4109,"activeCount":142},[],{"trials":4111,"activeCount":142},[4112],{"nctId":4113,"briefTitle":4114,"status":114,"phases":4115,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":95,"conditions":4118,"interventions":4120},"NCT02906397","Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)",[88],"2021-07-21","2017-03-30",[4119],"ADVANCED HEPATOCELLULAR CARCINOMA (HCC)",[4106],{"trials":4122,"activeCount":142},[],{"trials":4124,"activeCount":142},[],{"trials":4126,"activeCount":142},[],{"trials":4128,"activeCount":142},[],{"intervention":4130,"totalTrials":9,"cells":4131},"Carvedilol",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4150,"PHASE3":4152,"PHASE4":4154,"NA":4156},{"trials":4133,"activeCount":142},[],{"trials":4135,"activeCount":142},[4136],{"nctId":4137,"briefTitle":4138,"status":114,"phases":4139,"primaryCompletion":4140,"completion":4141,"start":4142,"enrollment":331,"conditions":4143,"interventions":4149},"NCT04023110","Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and\u002For Trastuzumab",[88],"2024-08-31","2025-01-14","2019-08-09",[4144,4145,4146,15,4147,4148],"Cardiotoxicity","Risk Factor, Cardiovascular","Toxicity Due to Chemotherapy","Cardiomyopathies","Heart Failure",[4130],{"trials":4151,"activeCount":142},[],{"trials":4153,"activeCount":142},[],{"trials":4155,"activeCount":142},[],{"trials":4157,"activeCount":142},[],{"intervention":3923,"totalTrials":9,"cells":4159},{"EARLY_PHASE1":4160,"PHASE1":4162,"PHASE2":4168,"PHASE3":4170,"PHASE4":4172,"NA":4174},{"trials":4161,"activeCount":142},[],{"trials":4163,"activeCount":142},[4164],{"nctId":3915,"briefTitle":3916,"status":114,"phases":4165,"primaryCompletion":3918,"completion":3919,"start":3920,"enrollment":378,"conditions":4166,"interventions":4167},[88],[2850,2861],[3923,3908],{"trials":4169,"activeCount":142},[],{"trials":4171,"activeCount":142},[],{"trials":4173,"activeCount":142},[],{"trials":4175,"activeCount":142},[],{"intervention":4177,"totalTrials":9,"cells":4178},"(PDT) Photodynamic therapy",{"EARLY_PHASE1":4179,"PHASE1":4181,"PHASE2":4192,"PHASE3":4194,"PHASE4":4196,"NA":4198},{"trials":4180,"activeCount":142},[],{"trials":4182,"activeCount":142},[4183],{"nctId":4184,"briefTitle":4185,"status":114,"phases":4186,"primaryCompletion":4187,"completion":4188,"start":3692,"enrollment":1453,"conditions":4189,"interventions":4191},"NCT01673074","HPPH and PDT for Pleural Malignancy",[88],"2013-12","2014-10-08",[4190],"Pleural Malignancy",[4177],{"trials":4193,"activeCount":142},[],{"trials":4195,"activeCount":142},[],{"trials":4197,"activeCount":142},[],{"trials":4199,"activeCount":142},[],{"intervention":4201,"totalTrials":9,"cells":4202},"irinotecan hydrochloride",{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4215,"PHASE3":4217,"PHASE4":4219,"NA":4221},{"trials":4204,"activeCount":142},[],{"trials":4206,"activeCount":142},[4207],{"nctId":4208,"briefTitle":4209,"status":114,"phases":4210,"start":4211,"conditions":4212,"interventions":4213},"NCT00002902","Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors",[88],"1997-04",[368],[4201,4214],"raltitrexed",{"trials":4216,"activeCount":142},[],{"trials":4218,"activeCount":142},[],{"trials":4220,"activeCount":142},[],{"trials":4222,"activeCount":142},[],{"intervention":4214,"totalTrials":9,"cells":4224},{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4233,"PHASE3":4235,"PHASE4":4237,"NA":4239},{"trials":4226,"activeCount":142},[],{"trials":4228,"activeCount":142},[4229],{"nctId":4208,"briefTitle":4209,"status":114,"phases":4230,"start":4211,"conditions":4231,"interventions":4232},[88],[368],[4201,4214],{"trials":4234,"activeCount":142},[],{"trials":4236,"activeCount":142},[],{"trials":4238,"activeCount":142},[],{"trials":4240,"activeCount":142},[],{"intervention":4242,"totalTrials":9,"cells":4243},"incomplete Freund's adjuvant",{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4258,"PHASE3":4260,"PHASE4":4262,"NA":4264},{"trials":4245,"activeCount":142},[],{"trials":4247,"activeCount":142},[4248],{"nctId":4249,"briefTitle":4250,"status":114,"phases":4251,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":580,"conditions":4254,"interventions":4255},"NCT00079157","Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer",[88],"2007-12","2004-02",[15],[4242,4256,4257],"sargramostim","telomerase: 540-548 peptide vaccine",{"trials":4259,"activeCount":142},[],{"trials":4261,"activeCount":142},[],{"trials":4263,"activeCount":142},[],{"trials":4265,"activeCount":142},[],{"intervention":4256,"totalTrials":9,"cells":4267},{"EARLY_PHASE1":4268,"PHASE1":4270,"PHASE2":4276,"PHASE3":4278,"PHASE4":4280,"NA":4282},{"trials":4269,"activeCount":142},[],{"trials":4271,"activeCount":142},[4272],{"nctId":4249,"briefTitle":4250,"status":114,"phases":4273,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":580,"conditions":4274,"interventions":4275},[88],[15],[4242,4256,4257],{"trials":4277,"activeCount":142},[],{"trials":4279,"activeCount":142},[],{"trials":4281,"activeCount":142},[],{"trials":4283,"activeCount":142},[],{"intervention":4257,"totalTrials":9,"cells":4285},{"EARLY_PHASE1":4286,"PHASE1":4288,"PHASE2":4294,"PHASE3":4296,"PHASE4":4298,"NA":4300},{"trials":4287,"activeCount":142},[],{"trials":4289,"activeCount":142},[4290],{"nctId":4249,"briefTitle":4250,"status":114,"phases":4291,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":580,"conditions":4292,"interventions":4293},[88],[15],[4242,4256,4257],{"trials":4295,"activeCount":142},[],{"trials":4297,"activeCount":142},[],{"trials":4299,"activeCount":142},[],{"trials":4301,"activeCount":142},[],{"intervention":4303,"totalTrials":9,"cells":4304},"Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI",{"EARLY_PHASE1":4305,"PHASE1":4307,"PHASE2":4320,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4306,"activeCount":142},[],{"trials":4308,"activeCount":142},[4309],{"nctId":4310,"briefTitle":4311,"status":114,"phases":4312,"primaryCompletion":2477,"completion":2477,"start":4313,"enrollment":22,"conditions":4314,"interventions":4317},"NCT00374933","Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation",[88],"2007-04",[2803,4315,4316],"Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome",[4303,4318,4319],"\"Prophylactic\" delayed ADLI","\"Prophylactic\" delayed activated donor lymphocyte",{"trials":4321,"activeCount":142},[],{"trials":4323,"activeCount":142},[],{"trials":4325,"activeCount":142},[],{"trials":4327,"activeCount":142},[],{"intervention":4318,"totalTrials":9,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4338,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4331,"activeCount":142},[],{"trials":4333,"activeCount":142},[4334],{"nctId":4310,"briefTitle":4311,"status":114,"phases":4335,"primaryCompletion":2477,"completion":2477,"start":4313,"enrollment":22,"conditions":4336,"interventions":4337},[88],[2803,4315,4316],[4303,4318,4319],{"trials":4339,"activeCount":142},[],{"trials":4341,"activeCount":142},[],{"trials":4343,"activeCount":142},[],{"trials":4345,"activeCount":142},[],{"intervention":4319,"totalTrials":9,"cells":4347},{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4356,"PHASE3":4358,"PHASE4":4360,"NA":4362},{"trials":4349,"activeCount":142},[],{"trials":4351,"activeCount":142},[4352],{"nctId":4310,"briefTitle":4311,"status":114,"phases":4353,"primaryCompletion":2477,"completion":2477,"start":4313,"enrollment":22,"conditions":4354,"interventions":4355},[88],[2803,4315,4316],[4303,4318,4319],{"trials":4357,"activeCount":142},[],{"trials":4359,"activeCount":142},[],{"trials":4361,"activeCount":142},[],{"trials":4363,"activeCount":142},[],{"intervention":4365,"totalTrials":9,"cells":4366},"OC-L",{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4378,"PHASE3":4380,"PHASE4":4382,"NA":4384},{"trials":4368,"activeCount":142},[],{"trials":4370,"activeCount":142},[4371],{"nctId":4372,"briefTitle":4373,"status":279,"phases":4374,"primaryCompletion":2267,"completion":2267,"start":3979,"enrollment":336,"conditions":4375,"interventions":4377},"NCT02452775","Autologous OC-L Vaccine and Ovarian Cancer",[88],[4376,2103,2104],"Primary Ovarian Cancer",[4365],{"trials":4379,"activeCount":142},[],{"trials":4381,"activeCount":142},[],{"trials":4383,"activeCount":142},[],{"trials":4385,"activeCount":142},[],{"intervention":583,"totalTrials":9,"cells":4387},{"EARLY_PHASE1":4388,"PHASE1":4390,"PHASE2":4396,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4389,"activeCount":142},[],{"trials":4391,"activeCount":142},[4392],{"nctId":575,"briefTitle":576,"status":114,"phases":4393,"primaryCompletion":578,"completion":578,"start":579,"enrollment":580,"conditions":4394,"interventions":4395},[88],[15],[583,568],{"trials":4397,"activeCount":142},[],{"trials":4399,"activeCount":142},[],{"trials":4401,"activeCount":142},[],{"trials":4403,"activeCount":142},[],{"intervention":4405,"totalTrials":9,"cells":4406},"Gliolan",{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4422,"PHASE3":4424,"PHASE4":4426,"NA":4428},{"trials":4408,"activeCount":142},[],{"trials":4410,"activeCount":142},[4411],{"nctId":4412,"briefTitle":4413,"status":138,"phases":4414,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":142,"conditions":4417,"interventions":4420},"NCT02698293","PDT Plus Vitamin D3 for Anal Dysplasia",[88],"2023-01-01","2019-12-01",[4418,4419],"Anal Dysplasia","Carcinoma in Situ",[4405,4421],"Vitamin D3 cholecalciferol)",{"trials":4423,"activeCount":142},[],{"trials":4425,"activeCount":142},[],{"trials":4427,"activeCount":142},[],{"trials":4429,"activeCount":142},[],{"intervention":4421,"totalTrials":9,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4446},{"trials":4433,"activeCount":142},[],{"trials":4435,"activeCount":142},[4436],{"nctId":4412,"briefTitle":4413,"status":138,"phases":4437,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":142,"conditions":4438,"interventions":4439},[88],[4418,4419],[4405,4421],{"trials":4441,"activeCount":142},[],{"trials":4443,"activeCount":142},[],{"trials":4445,"activeCount":142},[],{"trials":4447,"activeCount":142},[],{"intervention":3934,"totalTrials":9,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4451,"activeCount":142},[],{"trials":4453,"activeCount":142},[4454],{"nctId":3925,"briefTitle":3926,"status":114,"phases":4455,"primaryCompletion":3928,"completion":3928,"start":3929,"enrollment":439,"conditions":4456,"interventions":4457},[88],[3931,231,3932,15,519],[3934,3935],{"trials":4459,"activeCount":142},[],{"trials":4461,"activeCount":142},[],{"trials":4463,"activeCount":142},[],{"trials":4465,"activeCount":142},[],{"intervention":4467,"totalTrials":9,"cells":4468},"c-myb AS ODN",{"EARLY_PHASE1":4469,"PHASE1":4471,"PHASE2":4481,"PHASE3":4483,"PHASE4":4485,"NA":4487},{"trials":4470,"activeCount":142},[],{"trials":4472,"activeCount":142},[4473],{"nctId":4474,"briefTitle":4475,"status":114,"phases":4476,"primaryCompletion":1755,"completion":1755,"start":4477,"enrollment":28,"conditions":4478,"interventions":4480},"NCT00780052","Infusional C-myb ASODN in Advanced Hematologic Malignancies",[88],"2002-09",[4479],"Hematologic Malignancies",[4467],{"trials":4482,"activeCount":142},[],{"trials":4484,"activeCount":142},[],{"trials":4486,"activeCount":142},[],{"trials":4488,"activeCount":142},[],{"intervention":371,"totalTrials":9,"cells":4490},{"EARLY_PHASE1":4491,"PHASE1":4493,"PHASE2":4499,"PHASE3":4501,"PHASE4":4503,"NA":4505},{"trials":4492,"activeCount":142},[],{"trials":4494,"activeCount":142},[4495],{"nctId":360,"briefTitle":361,"status":114,"phases":4496,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":4497,"interventions":4498},[88],[368],[370,371],{"trials":4500,"activeCount":142},[],{"trials":4502,"activeCount":142},[],{"trials":4504,"activeCount":142},[],{"trials":4506,"activeCount":142},[],{"intervention":2402,"totalTrials":9,"cells":4508},{"EARLY_PHASE1":4509,"PHASE1":4511,"PHASE2":4517,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4510,"activeCount":142},[],{"trials":4512,"activeCount":142},[4513],{"nctId":2396,"briefTitle":2397,"status":114,"phases":4514,"start":2399,"conditions":4515,"interventions":4516},[88],[2201],[2402,2389,2403],{"trials":4518,"activeCount":142},[],{"trials":4520,"activeCount":142},[],{"trials":4522,"activeCount":142},[],{"trials":4524,"activeCount":142},[],{"intervention":2403,"totalTrials":9,"cells":4526},{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4541},{"trials":4528,"activeCount":142},[],{"trials":4530,"activeCount":142},[4531],{"nctId":2396,"briefTitle":2397,"status":114,"phases":4532,"start":2399,"conditions":4533,"interventions":4534},[88],[2201],[2402,2389,2403],{"trials":4536,"activeCount":142},[],{"trials":4538,"activeCount":142},[],{"trials":4540,"activeCount":142},[],{"trials":4542,"activeCount":142},[],{"intervention":2439,"totalTrials":9,"cells":4544},{"EARLY_PHASE1":4545,"PHASE1":4547,"PHASE2":4553,"PHASE3":4555,"PHASE4":4557,"NA":4559},{"trials":4546,"activeCount":142},[],{"trials":4548,"activeCount":142},[4549],{"nctId":2431,"briefTitle":2432,"status":279,"phases":4550,"primaryCompletion":2434,"completion":2434,"start":2435,"enrollment":252,"conditions":4551,"interventions":4552},[88],[2437],[2439,2424],{"trials":4554,"activeCount":142},[],{"trials":4556,"activeCount":142},[],{"trials":4558,"activeCount":142},[],{"trials":4560,"activeCount":142},[],{"intervention":4562,"totalTrials":9,"cells":4563},"OTL38",{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4575,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4565,"activeCount":142},[],{"trials":4567,"activeCount":142},[4568],{"nctId":4569,"briefTitle":4570,"status":138,"phases":4571,"primaryCompletion":4572,"completion":4572,"start":4572,"enrollment":142,"conditions":4573,"interventions":4574},"NCT04941378","OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer",[88],"2022-05-28",[27],[4562],{"trials":4576,"activeCount":142},[],{"trials":4578,"activeCount":142},[],{"trials":4580,"activeCount":142},[],{"trials":4582,"activeCount":142},[],{"intervention":2086,"totalTrials":9,"cells":4584},{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4599},{"trials":4586,"activeCount":142},[],{"trials":4588,"activeCount":142},[4589],{"nctId":2078,"briefTitle":2079,"status":114,"phases":4590,"primaryCompletion":2081,"completion":2082,"start":2083,"enrollment":19,"conditions":4591,"interventions":4592},[88],[106],[2086,434],{"trials":4594,"activeCount":142},[],{"trials":4596,"activeCount":142},[],{"trials":4598,"activeCount":142},[],{"trials":4600,"activeCount":142},[],{"intervention":1726,"totalTrials":9,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4604,"activeCount":142},[],{"trials":4606,"activeCount":142},[4607],{"nctId":1717,"briefTitle":1718,"status":114,"phases":4608,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":22,"conditions":4609,"interventions":4610},[88],[550,1723,1724],[870,1726,1706,1727],{"trials":4612,"activeCount":142},[],{"trials":4614,"activeCount":142},[],{"trials":4616,"activeCount":142},[],{"trials":4618,"activeCount":142},[],{"intervention":1727,"totalTrials":9,"cells":4620},{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4629,"PHASE3":4631,"PHASE4":4633,"NA":4635},{"trials":4622,"activeCount":142},[],{"trials":4624,"activeCount":142},[4625],{"nctId":1717,"briefTitle":1718,"status":114,"phases":4626,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":22,"conditions":4627,"interventions":4628},[88],[550,1723,1724],[870,1726,1706,1727],{"trials":4630,"activeCount":142},[],{"trials":4632,"activeCount":142},[],{"trials":4634,"activeCount":142},[],{"trials":4636,"activeCount":142},[],{"intervention":2095,"totalTrials":9,"cells":4638},{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4647,"PHASE3":4649,"PHASE4":4651,"NA":4653},{"trials":4640,"activeCount":142},[],{"trials":4642,"activeCount":142},[4643],{"nctId":2088,"briefTitle":2089,"status":279,"phases":4644,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":500,"conditions":4645,"interventions":4646},[88],[663],[2095,434],{"trials":4648,"activeCount":142},[],{"trials":4650,"activeCount":142},[],{"trials":4652,"activeCount":142},[],{"trials":4654,"activeCount":142},[],{"intervention":392,"totalTrials":9,"cells":4656},{"EARLY_PHASE1":4657,"PHASE1":4659,"PHASE2":4665,"PHASE3":4667,"PHASE4":4669,"NA":4671},{"trials":4658,"activeCount":142},[],{"trials":4660,"activeCount":142},[4661],{"nctId":384,"briefTitle":385,"status":114,"phases":4662,"primaryCompletion":387,"completion":387,"start":388,"enrollment":129,"conditions":4663,"interventions":4664},[88],[33],[370,391,392],{"trials":4666,"activeCount":142},[],{"trials":4668,"activeCount":142},[],{"trials":4670,"activeCount":142},[],{"trials":4672,"activeCount":142},[],{"intervention":2044,"totalTrials":9,"cells":4674},{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4683,"PHASE3":4685,"PHASE4":4687,"NA":4689},{"trials":4676,"activeCount":142},[],{"trials":4678,"activeCount":142},[4679],{"nctId":2038,"briefTitle":2039,"status":114,"phases":4680,"primaryCompletion":897,"completion":897,"start":2041,"enrollment":716,"conditions":4681,"interventions":4682},[88],[519],[2044,2045,2046],{"trials":4684,"activeCount":142},[],{"trials":4686,"activeCount":142},[],{"trials":4688,"activeCount":142},[],{"trials":4690,"activeCount":142},[],{"intervention":2106,"totalTrials":9,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4701,"PHASE3":4703,"PHASE4":4705,"NA":4707},{"trials":4694,"activeCount":142},[],{"trials":4696,"activeCount":142},[4697],{"nctId":2097,"briefTitle":2098,"status":279,"phases":4698,"primaryCompletion":2041,"completion":2100,"start":579,"enrollment":22,"conditions":4699,"interventions":4700},[88],[2102,2103,2104],[2106,434,2107,2108,2109],{"trials":4702,"activeCount":142},[],{"trials":4704,"activeCount":142},[],{"trials":4706,"activeCount":142},[],{"trials":4708,"activeCount":142},[],{"intervention":2107,"totalTrials":9,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4719,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4712,"activeCount":142},[],{"trials":4714,"activeCount":142},[4715],{"nctId":2097,"briefTitle":2098,"status":279,"phases":4716,"primaryCompletion":2041,"completion":2100,"start":579,"enrollment":22,"conditions":4717,"interventions":4718},[88],[2102,2103,2104],[2106,434,2107,2108,2109],{"trials":4720,"activeCount":142},[],{"trials":4722,"activeCount":142},[],{"trials":4724,"activeCount":142},[],{"trials":4726,"activeCount":142},[],{"intervention":2108,"totalTrials":9,"cells":4728},{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4737,"PHASE3":4739,"PHASE4":4741,"NA":4743},{"trials":4730,"activeCount":142},[],{"trials":4732,"activeCount":142},[4733],{"nctId":2097,"briefTitle":2098,"status":279,"phases":4734,"primaryCompletion":2041,"completion":2100,"start":579,"enrollment":22,"conditions":4735,"interventions":4736},[88],[2102,2103,2104],[2106,434,2107,2108,2109],{"trials":4738,"activeCount":142},[],{"trials":4740,"activeCount":142},[],{"trials":4742,"activeCount":142},[],{"trials":4744,"activeCount":142},[],{"intervention":2109,"totalTrials":9,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4755,"PHASE3":4757,"PHASE4":4759,"NA":4761},{"trials":4748,"activeCount":142},[],{"trials":4750,"activeCount":142},[4751],{"nctId":2097,"briefTitle":2098,"status":279,"phases":4752,"primaryCompletion":2041,"completion":2100,"start":579,"enrollment":22,"conditions":4753,"interventions":4754},[88],[2102,2103,2104],[2106,434,2107,2108,2109],{"trials":4756,"activeCount":142},[],{"trials":4758,"activeCount":142},[],{"trials":4760,"activeCount":142},[],{"trials":4762,"activeCount":142},[],{"intervention":4764,"totalTrials":9,"cells":4765},"MLN8237",{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4778,"PHASE3":4780,"PHASE4":4782,"NA":4784},{"trials":4767,"activeCount":142},[],{"trials":4769,"activeCount":142},[4770],{"nctId":4771,"briefTitle":4772,"status":114,"phases":4773,"primaryCompletion":4774,"start":2410,"enrollment":920,"conditions":4775,"interventions":4776},"NCT01540682","MLN8237 in Head and Neck Cancer",[88],"2015-11",[30],[4764,4777],"Cetuximab",{"trials":4779,"activeCount":142},[],{"trials":4781,"activeCount":142},[],{"trials":4783,"activeCount":142},[],{"trials":4785,"activeCount":142},[],{"intervention":4777,"totalTrials":9,"cells":4787},{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4796,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4789,"activeCount":142},[],{"trials":4791,"activeCount":142},[4792],{"nctId":4771,"briefTitle":4772,"status":114,"phases":4793,"primaryCompletion":4774,"start":2410,"enrollment":920,"conditions":4794,"interventions":4795},[88],[30],[4764,4777],{"trials":4797,"activeCount":142},[],{"trials":4799,"activeCount":142},[],{"trials":4801,"activeCount":142},[],{"trials":4803,"activeCount":142},[],{"intervention":609,"totalTrials":9,"cells":4805},{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4814,"PHASE3":4816,"PHASE4":4818,"NA":4820},{"trials":4807,"activeCount":142},[],{"trials":4809,"activeCount":142},[4810],{"nctId":603,"briefTitle":604,"status":114,"phases":4811,"primaryCompletion":189,"completion":189,"start":208,"enrollment":22,"conditions":4812,"interventions":4813},[88],[607],[609,568],{"trials":4815,"activeCount":142},[],{"trials":4817,"activeCount":142},[],{"trials":4819,"activeCount":142},[],{"trials":4821,"activeCount":142},[],{"intervention":4823,"totalTrials":9,"cells":4824},"DCVac-L",{"EARLY_PHASE1":4825,"PHASE1":4827,"PHASE2":4837,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4826,"activeCount":142},[],{"trials":4828,"activeCount":142},[4829],{"nctId":4830,"briefTitle":4831,"status":114,"phases":4832,"primaryCompletion":2477,"completion":2477,"start":3692,"enrollment":4833,"conditions":4834,"interventions":4836},"NCT00683241","A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer",[88],36,[27,4835],"Peritoneal Cancer",[4823],{"trials":4838,"activeCount":142},[],{"trials":4840,"activeCount":142},[],{"trials":4842,"activeCount":142},[],{"trials":4844,"activeCount":142},[],{"intervention":927,"totalTrials":9,"cells":4846},{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4855,"PHASE3":4857,"PHASE4":4859,"NA":4861},{"trials":4848,"activeCount":142},[],{"trials":4850,"activeCount":142},[4851],{"nctId":914,"briefTitle":915,"status":114,"phases":4852,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":4853,"interventions":4854},[88],[922,923,607,924,925],[775,927,928],{"trials":4856,"activeCount":142},[],{"trials":4858,"activeCount":142},[],{"trials":4860,"activeCount":142},[],{"trials":4862,"activeCount":142},[],{"intervention":928,"totalTrials":9,"cells":4864},{"EARLY_PHASE1":4865,"PHASE1":4867,"PHASE2":4873,"PHASE3":4875,"PHASE4":4877,"NA":4879},{"trials":4866,"activeCount":142},[],{"trials":4868,"activeCount":142},[4869],{"nctId":914,"briefTitle":915,"status":114,"phases":4870,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":4871,"interventions":4872},[88],[922,923,607,924,925],[775,927,928],{"trials":4874,"activeCount":142},[],{"trials":4876,"activeCount":142},[],{"trials":4878,"activeCount":142},[],{"trials":4880,"activeCount":142},[],{"intervention":4882,"totalTrials":9,"cells":4883},"Vaccine---primed, CD3\u002FCD28---costimulated autologous peripheral blood T---cells",{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4897,"PHASE3":4899,"PHASE4":4901,"NA":4903},{"trials":4885,"activeCount":142},[],{"trials":4887,"activeCount":142},[4888],{"nctId":4889,"briefTitle":4890,"status":138,"phases":4891,"primaryCompletion":4892,"start":2977,"enrollment":142,"conditions":4893,"interventions":4895},"NCT02277392","A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3\u002FCD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[88],"2015-06",[4894],"Ovarian, Fallopian Tube and Peritoneal Cancer",[4882,4896],"SB---485232",{"trials":4898,"activeCount":142},[],{"trials":4900,"activeCount":142},[],{"trials":4902,"activeCount":142},[],{"trials":4904,"activeCount":142},[],{"intervention":4896,"totalTrials":9,"cells":4906},{"EARLY_PHASE1":4907,"PHASE1":4909,"PHASE2":4915,"PHASE3":4917,"PHASE4":4919,"NA":4921},{"trials":4908,"activeCount":142},[],{"trials":4910,"activeCount":142},[4911],{"nctId":4889,"briefTitle":4890,"status":138,"phases":4912,"primaryCompletion":4892,"start":2977,"enrollment":142,"conditions":4913,"interventions":4914},[88],[4894],[4882,4896],{"trials":4916,"activeCount":142},[],{"trials":4918,"activeCount":142},[],{"trials":4920,"activeCount":142},[],{"trials":4922,"activeCount":142},[],{"intervention":404,"totalTrials":9,"cells":4924},{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4933,"PHASE3":4935,"PHASE4":4937,"NA":4939},{"trials":4926,"activeCount":142},[],{"trials":4928,"activeCount":142},[4929],{"nctId":394,"briefTitle":395,"status":114,"phases":4930,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":4931,"interventions":4932},[88],[368],[370,403,404,405],{"trials":4934,"activeCount":142},[],{"trials":4936,"activeCount":142},[],{"trials":4938,"activeCount":142},[],{"trials":4940,"activeCount":142},[],{"intervention":405,"totalTrials":9,"cells":4942},{"EARLY_PHASE1":4943,"PHASE1":4945,"PHASE2":4951,"PHASE3":4953,"PHASE4":4955,"NA":4957},{"trials":4944,"activeCount":142},[],{"trials":4946,"activeCount":142},[4947],{"nctId":394,"briefTitle":395,"status":114,"phases":4948,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":4949,"interventions":4950},[88],[368],[370,403,404,405],{"trials":4952,"activeCount":142},[],{"trials":4954,"activeCount":142},[],{"trials":4956,"activeCount":142},[],{"trials":4958,"activeCount":142},[],{"intervention":4960,"totalTrials":9,"cells":4961},"INCB099280",{"EARLY_PHASE1":4962,"PHASE1":4964,"PHASE2":4975,"PHASE3":4977,"PHASE4":4979,"NA":4981},{"trials":4963,"activeCount":142},[],{"trials":4965,"activeCount":142},[4966],{"nctId":4967,"briefTitle":4968,"status":138,"phases":4969,"primaryCompletion":4970,"completion":4971,"start":4972,"enrollment":142,"conditions":4973,"interventions":4974},"NCT06337162","Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)",[88],"2027-05-01","2028-09-01","2024-05-01",[550],[4960],{"trials":4976,"activeCount":142},[],{"trials":4978,"activeCount":142},[],{"trials":4980,"activeCount":142},[],{"trials":4982,"activeCount":142},[],{"intervention":4984,"totalTrials":9,"cells":4985},"recombinant adenovirus-hIFN-beta",{"EARLY_PHASE1":4986,"PHASE1":4988,"PHASE2":4998,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4987,"activeCount":142},[],{"trials":4989,"activeCount":142},[4990],{"nctId":4991,"briefTitle":4992,"status":114,"phases":4993,"primaryCompletion":4994,"completion":4994,"start":4995,"conditions":4996,"interventions":4997},"NCT00066404","Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions",[88],"2006-01","2003-04",[18],[4984],{"trials":4999,"activeCount":142},[],{"trials":5001,"activeCount":142},[],{"trials":5003,"activeCount":142},[],{"trials":5005,"activeCount":142},[],{"intervention":5007,"totalTrials":9,"cells":5008},"Rapamycin, Mitoxantrone, Etoposide, Cytarabine",{"EARLY_PHASE1":5009,"PHASE1":5011,"PHASE2":5022,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5010,"activeCount":142},[],{"trials":5012,"activeCount":142},[5013],{"nctId":5014,"briefTitle":5015,"status":114,"phases":5016,"primaryCompletion":1746,"completion":3374,"start":5017,"enrollment":25,"conditions":5018,"interventions":5020},"NCT00780104","Sirolimus in Combination With MEC in High Risk Myeloid Leukemias",[88],"2007-07",[5019,2367,979,2484],"Myeloid Leukemias",[5007,5021],"Rapamycin + MEC",{"trials":5023,"activeCount":142},[],{"trials":5025,"activeCount":142},[],{"trials":5027,"activeCount":142},[],{"trials":5029,"activeCount":142},[],{"intervention":5021,"totalTrials":9,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5040,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5033,"activeCount":142},[],{"trials":5035,"activeCount":142},[5036],{"nctId":5014,"briefTitle":5015,"status":114,"phases":5037,"primaryCompletion":1746,"completion":3374,"start":5017,"enrollment":25,"conditions":5038,"interventions":5039},[88],[5019,2367,979,2484],[5007,5021],{"trials":5041,"activeCount":142},[],{"trials":5043,"activeCount":142},[],{"trials":5045,"activeCount":142},[],{"trials":5047,"activeCount":142},[],{"intervention":4073,"totalTrials":9,"cells":5049},{"EARLY_PHASE1":5050,"PHASE1":5052,"PHASE2":5058,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5051,"activeCount":142},[],{"trials":5053,"activeCount":142},[5054],{"nctId":4063,"briefTitle":4064,"status":138,"phases":5055,"primaryCompletion":4066,"completion":4067,"start":4068,"enrollment":142,"conditions":5056,"interventions":5057},[88],[4070],[4072,4073],{"trials":5059,"activeCount":142},[],{"trials":5061,"activeCount":142},[],{"trials":5063,"activeCount":142},[],{"trials":5065,"activeCount":142},[],{"intervention":415,"totalTrials":9,"cells":5067},{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5069,"activeCount":142},[],{"trials":5071,"activeCount":142},[5072],{"nctId":407,"briefTitle":408,"status":114,"phases":5073,"primaryCompletion":410,"completion":411,"start":398,"enrollment":412,"conditions":5074,"interventions":5075},[88],[231],[42,415],{"trials":5077,"activeCount":142},[],{"trials":5079,"activeCount":142},[],{"trials":5081,"activeCount":142},[],{"trials":5083,"activeCount":142},[],{"intervention":5085,"totalTrials":9,"cells":5086},"therapeutic autologous dendritic cells",{"EARLY_PHASE1":5087,"PHASE1":5089,"PHASE2":5098,"PHASE3":5100,"PHASE4":5102,"NA":5104},{"trials":5088,"activeCount":142},[],{"trials":5090,"activeCount":142},[5091],{"nctId":5092,"briefTitle":5093,"status":114,"phases":5094,"primaryCompletion":2278,"completion":2278,"start":5095,"enrollment":104,"conditions":5096,"interventions":5097},"NCT00107211","Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast",[88],"2005-01",[15],[5085],{"trials":5099,"activeCount":142},[],{"trials":5101,"activeCount":142},[],{"trials":5103,"activeCount":142},[],{"trials":5105,"activeCount":142},[],{"intervention":5107,"totalTrials":9,"cells":5108},"Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily",{"EARLY_PHASE1":5109,"PHASE1":5118,"PHASE2":5120,"PHASE3":5122,"PHASE4":5124,"NA":5126},{"trials":5110,"activeCount":142},[5111],{"nctId":5112,"briefTitle":5113,"status":114,"phases":5114,"primaryCompletion":2506,"completion":5115,"start":3119,"enrollment":25,"conditions":5116,"interventions":5117},"NCT02331706","IFN-DLI for Relapsed Acute Leukemia After Allo-SCT",[87],"2017-11-11",[979],[5107],{"trials":5119,"activeCount":142},[],{"trials":5121,"activeCount":142},[],{"trials":5123,"activeCount":142},[],{"trials":5125,"activeCount":142},[],{"trials":5127,"activeCount":142},[],{"intervention":5129,"totalTrials":9,"cells":5130},"hTERT",{"EARLY_PHASE1":5131,"PHASE1":5140,"PHASE2":5142,"PHASE3":5144,"PHASE4":5146,"NA":5148},{"trials":5132,"activeCount":142},[5133],{"nctId":5134,"briefTitle":5135,"status":114,"phases":5136,"primaryCompletion":5137,"completion":5137,"start":2083,"enrollment":36,"conditions":5138,"interventions":5139},"NCT01660529","Multi-peptide Vaccine With Basilixumab for Breast Cancer",[87],"2015-11-20",[922],[5129],{"trials":5141,"activeCount":142},[],{"trials":5143,"activeCount":142},[],{"trials":5145,"activeCount":142},[],{"trials":5147,"activeCount":142},[],{"trials":5149,"activeCount":142},[],{"intervention":5151,"totalTrials":9,"cells":5152},"11C-Acetate",{"EARLY_PHASE1":5153,"PHASE1":5163,"PHASE2":5165,"PHASE3":5167,"PHASE4":5169,"NA":5171},{"trials":5154,"activeCount":142},[5155],{"nctId":5156,"briefTitle":5157,"status":114,"phases":5158,"primaryCompletion":5159,"completion":5159,"start":2697,"enrollment":198,"conditions":5160,"interventions":5162},"NCT02715583","C-Acetate PET\u002FCT Imaging to Evaluate Treatment Changes in Prostate Cancer",[87],"2020-09-25",[5161],"Prostate Cancer Patients",[5151],{"trials":5164,"activeCount":142},[],{"trials":5166,"activeCount":142},[],{"trials":5168,"activeCount":142},[],{"trials":5170,"activeCount":142},[],{"trials":5172,"activeCount":142},[],{"intervention":5174,"totalTrials":9,"cells":5175},"Blinatumomab",{"EARLY_PHASE1":5176,"PHASE1":5186,"PHASE2":5188,"PHASE3":5190,"PHASE4":5192,"NA":5194},{"trials":5177,"activeCount":142},[5178],{"nctId":5179,"briefTitle":5180,"status":279,"phases":5181,"primaryCompletion":5182,"completion":5182,"start":5183,"enrollment":198,"conditions":5184,"interventions":5185},"NCT03173430","Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma",[87],"2019-01-28","2017-05-27",[4036],[5174],{"trials":5187,"activeCount":142},[],{"trials":5189,"activeCount":142},[],{"trials":5191,"activeCount":142},[],{"trials":5193,"activeCount":142},[],{"trials":5195,"activeCount":142},[],{"intervention":5197,"totalTrials":9,"cells":5198},"Exjade®",{"EARLY_PHASE1":5199,"PHASE1":5210,"PHASE2":5212,"PHASE3":5214,"PHASE4":5216,"NA":5218},{"trials":5200,"activeCount":142},[5201],{"nctId":5202,"briefTitle":5203,"status":114,"phases":5204,"primaryCompletion":5205,"completion":388,"start":5206,"enrollment":378,"conditions":5207,"interventions":5209},"NCT02233504","Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)",[87],"2017-10","2014-08",[5208],"High Risk MDS or AML Patients",[5197],{"trials":5211,"activeCount":142},[],{"trials":5213,"activeCount":142},[],{"trials":5215,"activeCount":142},[],{"trials":5217,"activeCount":142},[],{"trials":5219,"activeCount":142},[],{"intervention":5221,"totalTrials":9,"cells":5222},"Pazopanib",{"EARLY_PHASE1":5223,"PHASE1":5234,"PHASE2":5236,"PHASE3":5238,"PHASE4":5240,"NA":5242},{"trials":5224,"activeCount":142},[5225],{"nctId":5226,"briefTitle":5227,"status":114,"phases":5228,"primaryCompletion":4892,"completion":5229,"start":5230,"enrollment":129,"conditions":5231,"interventions":5233},"NCT01221506","Pazopanib\u002FDCE-MRIs in Renal Cell Carcinoma (RCC)",[87],"2019-04","2010-10",[5232],"Carcinoma, Renal Cell",[5221],{"trials":5235,"activeCount":142},[],{"trials":5237,"activeCount":142},[],{"trials":5239,"activeCount":142},[],{"trials":5241,"activeCount":142},[],{"trials":5243,"activeCount":142},[],{"intervention":5245,"totalTrials":9,"cells":5246},"Zirconium Zr 89 Crefmirlimab Berdoxa",{"EARLY_PHASE1":5247,"PHASE1":5257,"PHASE2":5259,"PHASE3":5261,"PHASE4":5263,"NA":5265},{"trials":5248,"activeCount":142},[5249],{"nctId":5250,"briefTitle":5251,"status":114,"phases":5252,"primaryCompletion":5253,"completion":5253,"start":5254,"enrollment":198,"conditions":5255,"interventions":5256},"NCT05279027","Zr89 + PET Companion Trial",[87],"2025-05-06","2022-03-08",[2181],[5245],{"trials":5258,"activeCount":142},[],{"trials":5260,"activeCount":142},[],{"trials":5262,"activeCount":142},[],{"trials":5264,"activeCount":142},[],{"trials":5266,"activeCount":142},[],{"intervention":5268,"totalTrials":9,"cells":5269},"OCDC",{"EARLY_PHASE1":5270,"PHASE1":5281,"PHASE2":5283,"PHASE3":5285,"PHASE4":5287,"NA":5289},{"trials":5271,"activeCount":142},[5272],{"nctId":5273,"briefTitle":5274,"status":114,"phases":5275,"primaryCompletion":2267,"completion":2267,"start":5276,"enrollment":303,"conditions":5277,"interventions":5280},"NCT01132014","Autologous OC-DC Vaccine in Ovarian Cancer",[87],"2010-05",[5278,5279,27],"Chemotherapy","Tumor",[5268],{"trials":5282,"activeCount":142},[],{"trials":5284,"activeCount":142},[],{"trials":5286,"activeCount":142},[],{"trials":5288,"activeCount":142},[],{"trials":5290,"activeCount":142},[],{"intervention":3635,"totalTrials":500,"cells":5292},{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5297,"PHASE3":5303,"PHASE4":5305,"NA":5307},{"trials":5294,"activeCount":142},[],{"trials":5296,"activeCount":142},[],{"trials":5298,"activeCount":142},[5299],{"nctId":3624,"briefTitle":3625,"status":3626,"phases":5300,"primaryCompletion":3628,"start":399,"enrollment":129,"conditions":5301,"interventions":5302},[89],[3630],[3632,3633,3615,3634,3635,3636],{"trials":5304,"activeCount":142},[],{"trials":5306,"activeCount":142},[],{"trials":5308,"activeCount":142},[5309],{"nctId":5310,"briefTitle":5311,"status":114,"phases":5312,"primaryCompletion":1419,"completion":897,"start":2199,"enrollment":5313,"conditions":5314,"interventions":5317},"NCT01026337","Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer",[],43,[106,5315,5316],"Stage III Renal Cell Cancer","Stage IV Renal Cell Cancer",[3635,3633],{"intervention":3633,"totalTrials":500,"cells":5319},{"EARLY_PHASE1":5320,"PHASE1":5322,"PHASE2":5324,"PHASE3":5330,"PHASE4":5332,"NA":5334},{"trials":5321,"activeCount":142},[],{"trials":5323,"activeCount":142},[],{"trials":5325,"activeCount":142},[5326],{"nctId":3624,"briefTitle":3625,"status":3626,"phases":5327,"primaryCompletion":3628,"start":399,"enrollment":129,"conditions":5328,"interventions":5329},[89],[3630],[3632,3633,3615,3634,3635,3636],{"trials":5331,"activeCount":142},[],{"trials":5333,"activeCount":142},[],{"trials":5335,"activeCount":142},[5336],{"nctId":5310,"briefTitle":5311,"status":114,"phases":5337,"primaryCompletion":1419,"completion":897,"start":2199,"enrollment":5313,"conditions":5338,"interventions":5339},[],[106,5315,5316],[3635,3633],{"intervention":3632,"totalTrials":500,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5343,"activeCount":142},[],{"trials":5345,"activeCount":142},[],{"trials":5347,"activeCount":142},[5348],{"nctId":3624,"briefTitle":3625,"status":3626,"phases":5349,"primaryCompletion":3628,"start":399,"enrollment":129,"conditions":5350,"interventions":5351},[89],[3630],[3632,3633,3615,3634,3635,3636],{"trials":5353,"activeCount":142},[],{"trials":5355,"activeCount":142},[],{"trials":5357,"activeCount":142},[5358],{"nctId":5359,"briefTitle":5360,"status":114,"phases":5361,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5365,"interventions":5366},"NCT00003736","MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer",[92],"2002-06","1999-06",200,[15],[3632],{"intervention":5368,"totalTrials":9,"cells":5369},"Lyrica 300 mg",{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5378,"NA":5380},{"trials":5371,"activeCount":142},[],{"trials":5373,"activeCount":142},[],{"trials":5375,"activeCount":142},[],{"trials":5377,"activeCount":142},[],{"trials":5379,"activeCount":142},[],{"trials":5381,"activeCount":142},[5382],{"nctId":5383,"briefTitle":5384,"status":114,"phases":5385,"primaryCompletion":5386,"completion":5386,"start":5387,"enrollment":129,"conditions":5388,"interventions":5391},"NCT02277548","A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.",[92],"2018-04","2014-05",[5389,5390],"Oropharyngeal Cancer","Squamous Cell Carcinoma to the Head and Neck",[5368],{"intervention":5393,"totalTrials":9,"cells":5394},"fluorine F18 EF5",{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5399,"PHASE3":5401,"PHASE4":5403,"NA":5405},{"trials":5396,"activeCount":142},[],{"trials":5398,"activeCount":142},[],{"trials":5400,"activeCount":142},[],{"trials":5402,"activeCount":142},[],{"trials":5404,"activeCount":142},[],{"trials":5406,"activeCount":142},[5407],{"nctId":5408,"briefTitle":5409,"status":114,"phases":5410,"primaryCompletion":4187,"completion":4187,"start":5411,"enrollment":252,"conditions":5412,"interventions":5414},"NCT01020097","Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx",[92],"2009-03",[5413],"Squamous Cell Carcinoma",[5393],{"intervention":5416,"totalTrials":9,"cells":5417},"Genetic Providers",{"EARLY_PHASE1":5418,"PHASE1":5420,"PHASE2":5422,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5419,"activeCount":142},[],{"trials":5421,"activeCount":142},[],{"trials":5423,"activeCount":142},[],{"trials":5425,"activeCount":142},[],{"trials":5427,"activeCount":142},[],{"trials":5429,"activeCount":142},[5430],{"nctId":5431,"briefTitle":5432,"status":114,"phases":5433,"primaryCompletion":4774,"completion":4774,"start":5434,"enrollment":5435,"conditions":5436,"interventions":5438},"NCT01736345","A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study",[],"2012-12-03",289,[5437],"Candidates for BRCA 1\u002F2 Genetic Testing",[5416]]